<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SELZENTRYÂ - maravirocÂ tablet, film coatedÂ </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use SELZENTRY safely and effectively. See full prescribing information for SELZENTRY.SELZENTRY (maraviroc) Tablets, for oral useInitial U.S. Approval: 2007</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>Boxed Warning section</h1>
<a href="http://"></a><p class="First"></p>
<p><span class="Bold">Hepatotoxicity has been reported with use of SELZENTRY. Severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or evidence of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, or elevated IgE) prior to the development of hepatotoxicity may occur. Patients with signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> following use of SELZENTRY should be evaluated immediately <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</span></p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<a href="http://"></a><p class="First"></p>
<p>SELZENTRY, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1.</p>
<p>This indication is based on analyses of plasma HIVâ€‘1 RNA levels in 2Â controlled trials of SELZENTRY in treatmentâ€‘experienced subjects and one trial in treatmentâ€‘naive subjects. Both trials in treatment-experienced subjects were conducted in clinically advanced, 3-class antiretroviralâ€‘experienced (nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], protease inhibitor [PI], or enfuvirtide) adults with evidence of HIVâ€‘1 replication despite ongoing antiretroviral therapy.  </p>
<p>The following points should be considered when initiating therapy with SELZENTRY:</p>
<ul>
<li>Adult patients infected with only CCR5-tropic HIV-1 should use SELZENTRY. </li>
<li>Tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for use of SELZENTRY. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on SELZENTRY <span class="Italics">[see Microbiology (12.4), Clinical Studies (14.3)]</span>.</li>
<li>Use of SELZENTRY is not recommended in subjects with dual/mixed- or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a Phase 2 trial of this patient group.</li>
<li>The safety and efficacy of SELZENTRY have not been established in pediatric patients.</li>
<li>In treatment-naive subjects, more subjects treated with SELZENTRY experienced virologic failure and developed lamivudine resistance compared with efavirenz <span class="Italics">[see Microbiology (12.4), Clinical Studies (14.3)]</span>.</li>
</ul>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<a href="http://"></a><p class="First"></p>
<p>The recommended dose of SELZENTRY differs based on concomitant medications due to drug interactions (see Table 1). SELZENTRY can be taken with or without food. SELZENTRY must be given in combination with other antiretroviral medications.</p>
<p>Table 1 gives the recommended dose adjustments <span class="Italics">[see Drug Interactions (7.1)]</span>.</p>
<a name="_Refid_01905207-d216-4ac5-beaa-aa7e057ad"></a><table>
<caption><span>Table 1. Recommended Dosing Regimen</span></caption>
<col span="1" width="93%">
<col span="1" width="22%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Concomitant Medications</p></td>
<td><p class="First">Dose of SELZENTRY</p></td>
</tr>
<tr>
<td>
<p class="First">Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including:</p>
<ul>
<li>protease inhibitors (except tipranavir/ritonavir)</li>
<li>delavirdine</li>
<li>ketoconazole, itraconazole, clarithromycin</li>
<li>other potent CYP3A inhibitors (e.g., nefazodone, telithromycin)</li>
</ul>
</td>
<td><p class="First">150Â mg twice daily</p></td>
</tr>
<tr>
<td><p class="First">Other concomitant medications, including tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide </p></td>
<td><p class="First">300Â mg twice daily</p></td>
</tr>
<tr class="Last">
<td>
<p class="First">Potent CYP3A inducers (without a potent CYP3A inhibitor) including:</p>
<ul>
<li>efavirenz</li>
<li>rifampin</li>
<li>etravirine</li>
<li>carbamazepine, phenobarbital, and phenytoin</li>
</ul>
</td>
<td><p class="First">600Â mg twice daily</p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Table 2 provides dosing recommendations for patients based on renal function and concomitant medications.</p>
<a name="_Refid_eafac2fc-3a31-47af-83ae-df3505b77"></a><table>
<caption><span>Table 2. Recommended Dosing Regimens Based on Renal Function</span></caption>
<col span="1" width="32%">
<col span="1" width="15%">
<col span="1" width="17%">
<col span="1" width="18%">
<col span="1" width="14%">
<col span="1" width="19%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Concomitant Medications<span class="Sup">a</span></p></td>
<td><p class="First">Dose of SELZENTRY Based on Renal Function</p></td>
</tr>
<tr>
<td>
<p class="First">Normal</p>
<p>(CrCl&gt;80 mL/min)</p>
</td>
<td>
<p class="First">Mild</p>
<p>(CrCl &gt;50 and â‰¤80 mL/min)</p>
</td>
<td>
<p class="First">Moderate</p>
<p>(CrCl â‰¥30 and â‰¤50 mL/min)</p>
</td>
<td>
<p class="First">Severe</p>
<p>(CrCl &lt;30 mL/min)</p>
</td>
<td>
<p class="First">End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> </p>
<p>On Regular Hemodialysis</p>
</td>
</tr>
<tr>
<td><p class="First">Potent CYP3A inhibitors (with or without a CYP3A inducer)<span class="Sup">a</span></p></td>
<td><p class="First">150Â mg twice daily</p></td>
<td><p class="First">150Â mg twice daily</p></td>
<td><p class="First">150 mg twice daily</p></td>
<td><p class="First">NR</p></td>
<td><p class="First">NR</p></td>
</tr>
<tr>
<td><p class="First">Other concomitant medications<span class="Sup">a</span></p></td>
<td><p class="First">300Â mg twice daily</p></td>
<td><p class="First">300Â mg twice daily</p></td>
<td><p class="First">300Â mg twice daily</p></td>
<td><p class="First">300Â mg twice daily<span class="Sup">b</span></p></td>
<td><p class="First">300Â mg twice daily<span class="Sup">b</span></p></td>
</tr>
<tr class="Last">
<td><p class="First">Potent CYP3A Inducers (without a potent CYP3A inhibitor)<span class="Sup">a</span></p></td>
<td><p class="First">600Â mg twice daily</p></td>
<td><p class="First">600Â mg twice daily</p></td>
<td><p class="First">600Â mg twice daily</p></td>
<td><p class="First">NR</p></td>
<td><p class="First">NR</p></td>
</tr>
</tbody>
</table>
<p>NRÂ =Â Not recommended.</p>
<p><span class="Sup">a</span>See Table 1 for the list of concomitant medications.</p>
<p><span class="Sup">b</span>The dose of SELZENTRY should be reduced to 150Â mg twice daily if there are any symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<a href="http://"></a><p class="First"></p>
<ul>
<li>150-mg blue, oval, film-coated tablets debossed with â€œMVC 150â€? on one side and plain on the other.</li>
<li>300-mg blue, oval, film-coated tablets debossed with â€œMVC 300â€? on one side and plain on the other.</li>
</ul>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>SELZENTRY should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) (CrCl &lt;30 mL/min) who are taking potent CYP3A inhibitors or inducers.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p> Hepatotoxicity with allergic features including life-threatening events has been reported in clinical trials and postmarketing. Severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or evidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> including drug-related <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, elevated IgE, or other systemic symptoms have been reported in conjunction with hepatotoxicity <span class="Italics">[see Warnings and Precautions (5.2)]</span>. These events occurred approximately 1 month after starting treatment. Among reported cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, some were observed in the absence of allergic features or with no pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
<p> Appropriate laboratory testing including ALT, AST, and bilirubin should be conducted prior to initiating therapy with SELZENTRY and at other timepoints during treatment as clinically indicated. Hepatic laboratory parameters should be obtained in any patient who develops <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Discontinuation of SELZENTRY should be considered in any patient with signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, or with increased liver transaminases combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic symptoms.</p>
<p> Caution should be used when administering SELZENTRY to patients with pre-existing liver dysfunction or who are co-infected with <span class="product-label-link" type="condition" conceptid="4281232" conceptname="Type B viral hepatitis">viral hepatitis B</span> or C. The safety and efficacy of SELZENTRY have not been specifically studied in patients with significant underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span>. In trials of treatment-experienced HIV-1-infected subjects, approximately 6% of subjects were co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and approximately 6% were co-infected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C. Due to the small number of co-infected subjects studied, no conclusions can be drawn regarding whether they are at an increased risk for hepatic adverse events with administration of SELZENTRY.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p><span>Severe, potentially life-threatening skin and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported in patients taking SELZENTRY, in most cases concomitantly with other drugs associated with these reactions. These include cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), and <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS) [see Adverse Reactions (6.2)]. The cases were characterized by features including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and sometimes organ dysfunction, including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>. Discontinue SELZENTRY and other suspected agents immediately if signs or symptoms of severe skin or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> develop (including, but not limited to, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">lip swelling</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>). Delay in stopping treatment with SELZENTRY or other suspect drugs after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may result in a life-threatening reaction. Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated.</span></p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Use with caution in patients at increased risk for cardiovascular events. Eleven subjects (1.3%) who received SELZENTRY had cardiovascular events, including <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, during the Phase 3 trials in treatment-experienced subjects (total exposure 609 patient-years [300 on SELZENTRY once daily + 309 on SELZENTRY twice daily]), while no subjects who received placebo had such events (total exposure 111Â patient-years). These subjects generally had cardiac disease or cardiac risk factors prior to use of SELZENTRY, and the relative contribution of SELZENTRY to these events is not known.</p>
<p>In the Phase 2b/3 trial in treatment-naive subjects, 3 subjects (0.8%) who received SELZENTRY had events related to <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart diseases</span> and 5 subjects (1.4%) who received efavirenz had such events (total exposure 506 and 508 patient-years for SELZENTRY and efavirenz, respectively).</p>
<p>When SELZENTRY was administered to healthy volunteers at doses higher than the recommended dose, symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> was seen at a greater frequency than in placebo. However, when SELZENTRY was given at the recommended dose in HIV-1-infected subjects in Phase 3 trials, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> was seen at a rate similar to placebo (approximately 0.5%). Caution should be used when administering SELZENTRY in patients with a history of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> or on concomitant medication known to lower blood pressure.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural Hypotension</span> in Patients </span><span class="Underline">With</span><span class="Underline"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may have cardiovascular co-morbidities and could be at increased risk of cardiovascular adverse events triggered by <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. An increased risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> may occur in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> or in those with ESRD due to increased maraviroc exposure in some patients. SELZENTRY should be used in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD only if they are not receiving a concomitant potent CYP3A inhibitor or inducer. However, the use of SELZENTRY in these patients should only be considered when no alternative treatment options are available. If patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD experience any symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> while taking 300Â mg twice daily, the dose should be reduced to 150Â mg twice daily <span class="Italics">[see Dosage and Administration (2.2)]</span>.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including SELZENTRY. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">Mycobacterium avium </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis</span> jirovecii <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, or reactivation of <span class="Italics">Herpes</span> simplex and <span class="Italics">Herpes</span> zoster), which may necessitate further evaluation and treatment.</p>
<p><span><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</span></p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>SELZENTRY antagonizes the CCR5 co-receptor located on some immune cells, and therefore could potentially increase the risk of developing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The overall incidence and severity of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, as well as AIDS-defining category C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, was comparable in the treatment groups during the Phase 3 treatment-experienced trials of SELZENTRY. While there was a higher rate of certain <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> reported in the arm receiving SELZENTRY compared with placebo (23% versus 13%), there was a lower rate of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (2% versus 5%) reported in subjects receiving SELZENTRY. A higher incidence of <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">Herpes virus infections</span> (11 per 100Â patient-years) was also reported in the arm receiving SELZENTRY when adjusted for exposure compared with placebo (8 per 100Â patient-years).</p>
<p>In the Phase 2b/3 trial in treatment-naive subjects, the incidence of AIDS-defining Category C events when adjusted for exposure was 1.8 for SELZENTRY compared with 2.4 for efavirenz per 100Â patient-years of exposure.</p>
<p>Patients should be monitored closely for evidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> while receiving SELZENTRY.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>While no increase in malignancy has been observed with SELZENTRY, due to this drugâ€™s mechanism of action it could affect immune surveillance and lead to an increased risk of malignancy.</p>
<p>The exposure-adjusted rate for malignancies per 100 patient-years of exposure in treatment-experienced trials was 4.6 for SELZENTRY compared with 9.3 on placebo. In treatment-naive subjects, the rates were 1.0 and 2.4 per 100Â patient-years of exposure for SELZENTRY and efavirenz, respectively.</p>
<p>Long-term follow-up is needed to more fully assess this risk.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>The following adverse reactions are discussed in other sections of the labeling:</p>
<ul>
<li>Hepatotoxicity <span class="Italics">[see Boxed Warning, Warnings and Precautions (5.1)]</span>
</li>
<li>Severe Skin and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</li>
<li>Cardiovascular events <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</li>
</ul>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Underline">Trials in Treatment-Experienced Subjects:</span> The safety profile of SELZENTRY is primarily based on 840 HIV-1-infected subjects who received at least 1 dose of SELZENTRY during two Phase 3 trials. A total of 426 of these subjects received the indicated twice-daily dosing regimen.</p>
<p>Assessment of treatment-emergent adverse events is based on the pooled data from 2 trials in subjects with CCR5-tropic HIV-1 (A4001027 and A4001028). The median duration of therapy with SELZENTRY for subjects in these trials was 48 weeks, with the total exposure on SELZENTRY twice daily at 309 patient-years versus 111 patient-years on placebo + optimized background therapy (OBT). The population was 89% male and 84% white, with mean age of 46 years (range: 17 to 75 years). Subjects received dose equivalents of 300Â mg maraviroc once or twice daily.</p>
<p>The most common adverse events reported with twice-daily therapy with SELZENTRY with frequency rates higher than placebo, regardless of causality, were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Additional adverse events that occurred with once-daily dosing at a higher rate than both placebo and twice-daily dosing were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="440087" conceptname="Parasomnia">parasomnias</span>, and urinary abnormalities. In these 2Â trials, the rate of discontinuation due to adverse events was 5% for subjects who received SELZENTRY twice daily + OBT as well as those who received placebo + OBT. Most of the adverse events reported were judged to be mild to moderate in severity. The data described below occurred with twice-daily dosing of SELZENTRY.</p>
<p>The total number of subjects reporting <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were 233 (55%) and 84 (40%) in the group receiving SELZENTRY twice daily and the placebo group, respectively. Correcting for the longer duration of exposure on SELZENTRY compared with placebo, the exposure-adjusted frequency (rate per 100 subject-years) of these events was 133 for both SELZENTRY twice daily and placebo.</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> occurred in 8% of subjects on either SELZENTRY or placebo, with 2 subjects (0.5%) on SELZENTRY permanently discontinuing therapy (1 due to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, 1 due to <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>) versus 1 subject on placebo (0.5%) permanently discontinuing therapy due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Treatment-emergent adverse events, regardless of causality, from A4001027 and A4001028 are summarized in Table 3. Selected events occurring at â‰¥2% of subjects and at a numerically higher rate in subjects treated with SELZENTRY are included; events that occurred at the same or higher rate on placebo are not displayed.</p>
<a name="_Refid_dbab6b4c-f413-443c-ba9e-7498c7532"></a><table>
<caption><span>Table 3. Percentage of Subjects With Selected Treatment-Emergent Adverse Events (All Causality)(â‰¥2% on SELZENTRY and at a higher rate compared with placebo) Trials A4001027 and A4001028 (Pooled Analysis, 48 Weeks)</span></caption>
<col span="1" width="53%">
<col span="1" width="10%">
<col span="1" width="21%">
<col span="1" width="10%">
<col span="1" width="21%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First">SELZENTRY</p>
<p>Twice Daily<span class="Sup">a</span></p>
</td>
<td><p class="First">Placebo</p></td>
</tr>
<tr>
<td></td>
<td>
<p class="First">NÂ =Â 426</p>
<p>(%)</p>
</td>
<td>
<p class="First">Exposure-adjusted rate</p>
<p>(per 100 pt-yrs)</p>
<p>PYEÂ =Â 309<span class="Sup">b</span></p>
</td>
<td>
<p class="First">NÂ =Â 209</p>
<p>(%)</p>
</td>
<td>
<p class="First">Exposure-adjusted rate</p>
<p>(per 100 pt-yrs)</p>
<p>PYEÂ =Â 111<span class="Sup">b</span></p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span> </p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">1</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">Ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span>, and associated manifestations</p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">1</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td><p class="First">6</p></td>
<td><p class="First">9</p></td>
<td><p class="First">3</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </p></td>
<td><p class="First">13</p></td>
<td><p class="First">20</p></td>
<td><p class="First">9</p></td>
<td><p class="First">17</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> </p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td><p class="First">23</p></td>
<td><p class="First">37</p></td>
<td><p class="First">13</p></td>
<td><p class="First">27</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">Herpes infection</span></p></td>
<td><p class="First">8</p></td>
<td><p class="First">11</p></td>
<td><p class="First">4</p></td>
<td><p class="First">8</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td><p class="First">7</p></td>
<td><p class="First">10</p></td>
<td><p class="First">3</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td><p class="First">7</p></td>
<td><p class="First">9</p></td>
<td><p class="First">5</p></td>
<td><p class="First">9</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span></p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">2</p></td>
<td><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">5</p></td>
<td><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">Anogenital warts</span> </p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">1</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span> </p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">0.5</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span></p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">0.5</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Metabolism and Nutrition Disorders</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Appetite disorders</p></td>
<td><p class="First">8</p></td>
<td><p class="First">11</p></td>
<td><p class="First">7</p></td>
<td><p class="First">13</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Joint-related signs and symptoms</p></td>
<td><p class="First">7</p></td>
<td><p class="First">10</p></td>
<td><p class="First">3</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pains</span></p></td>
<td><p class="First">3</p></td>
<td><p class="First">4</p></td>
<td><p class="First">0.5</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Neoplasms Benign, Malignant, and Unspecified</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Skin neoplasms benign</p></td>
<td><p class="First">3</p></td>
<td><p class="First">4</p></td>
<td><p class="First">1</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </p></td>
<td><p class="First">9</p></td>
<td><p class="First">13</p></td>
<td><p class="First">8</p></td>
<td><p class="First">17</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span></p></td>
<td><p class="First">5</p></td>
<td><p class="First">7</p></td>
<td><p class="First">3</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">Sensory abnormalities</p></td>
<td><p class="First">4</p></td>
<td><p class="First">6</p></td>
<td><p class="First">1</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">Disturbances in consciousness</p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">Peripheral neuropathies</p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Disturbances in initiating and maintaining sleep</p></td>
<td><p class="First">8</p></td>
<td><p class="First">11</p></td>
<td><p class="First">5</p></td>
<td><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td><p class="First">4</p></td>
<td><p class="First">6</p></td>
<td><p class="First">3</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> symptoms</p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">3</p></td>
<td><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Renal and Urinary Disorders</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Bladder and urethral symptoms</p></td>
<td><p class="First">5</p></td>
<td><p class="First">7</p></td>
<td><p class="First">1</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First">Urinary tract signs and symptoms</p></td>
<td><p class="First">3</p></td>
<td><p class="First">4</p></td>
<td><p class="First">1</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span> and associated symptoms </p></td>
<td><p class="First">14</p></td>
<td><p class="First">21</p></td>
<td><p class="First">5</p></td>
<td><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First">Upper respiratory tract signs and symptoms</p></td>
<td><p class="First">6</p></td>
<td><p class="First">9</p></td>
<td><p class="First">3</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammations</span> </p></td>
<td><p class="First">4</p></td>
<td><p class="First">6</p></td>
<td><p class="First">3</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">Breathing abnormalities</p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">2</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">Paranasal sinus disorders </p></td>
<td><p class="First">3</p></td>
<td><p class="First">4</p></td>
<td><p class="First">0.5</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </p></td>
<td><p class="First">11</p></td>
<td><p class="First">16</p></td>
<td><p class="First">5</p></td>
<td><p class="First">11</p></td>
</tr>
<tr>
<td><p class="First">Apocrine and eccrine gland disorders</p></td>
<td><p class="First">5</p></td>
<td><p class="First">7</p></td>
<td><p class="First">4</p></td>
<td><p class="First">7.5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> </p></td>
<td><p class="First">4</p></td>
<td><p class="First">5</p></td>
<td><p class="First">2</p></td>
<td><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">Lipodystrophies </p></td>
<td><p class="First">3</p></td>
<td><p class="First">5</p></td>
<td><p class="First">0.5</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythemas</span></p></td>
<td><p class="First">2</p></td>
<td><p class="First">3</p></td>
<td><p class="First">1</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td><p class="First">Vascular hypertensive disorders</p></td>
<td><p class="First">3</p></td>
<td><p class="First">4</p></td>
<td><p class="First">2</p></td>
<td><p class="First">4</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>300-mg dose equivalent.Â  </p>
<p><span class="Sup">b</span>PYE = Patient-years of exposure.</p>
<p>Laboratory Abnormalities: Table 4 shows the treatment-emergent Grade 3-4 laboratory abnormalities that occurred in &gt;2% of subjects receiving SELZENTRY.<span class="Bold">Table 4. Maximum Shift in Laboratory Test Values (Without Regard to Baseline)</span></p>
<p><span class="Bold">Incidence â‰¥2% of Grade 3-4 Abnormalities (ACTG Criteria) Trials A4001027 and A4001028 (Pooled Analysis, 48 Weeks)</span></p>
<table>
<col span="1" width="37%">
<col span="1" width="13%">
<col span="1" width="21%">
<col span="1" width="17%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Laboratory Parameter Preferred Term</p></td>
<td><p class="First">Limit</p></td>
<td>
<p class="First">SELZENTRY</p>
<p>Twice Daily + OBT</p>
<p>(NÂ =Â 421)<span class="Sup">a</span></p>
<p>%</p>
</td>
<td>
<p class="First">Placebo + OBT</p>
<p>(NÂ =Â 207)<span class="Sup">a</span></p>
<p>%</p>
</td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span></p></td>
<td><p class="First">&gt;5.0x ULN</p></td>
<td><p class="First">4.8</p></td>
<td><p class="First">2.9</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span></p></td>
<td><p class="First">&gt;5.0x ULN</p></td>
<td><p class="First">2.6</p></td>
<td><p class="First">3.4</p></td>
</tr>
<tr>
<td><p class="First">Total bilirubin</p></td>
<td><p class="First">&gt;5.0x ULN</p></td>
<td><p class="First">5.5</p></td>
<td><p class="First">5.3</p></td>
</tr>
<tr>
<td><p class="First">Amylase</p></td>
<td><p class="First">&gt;2.0x ULN</p></td>
<td><p class="First">5.7</p></td>
<td><p class="First">5.8</p></td>
</tr>
<tr>
<td><p class="First">Lipase</p></td>
<td><p class="First">&gt;2.0x ULN</p></td>
<td><p class="First">4.9</p></td>
<td><p class="First">6.3</p></td>
</tr>
<tr class="Last">
<td><p class="First">Absolute neutrophil count</p></td>
<td><p class="First">&lt;750/mm<span class="Sup">3</span></p></td>
<td><p class="First">4.3</p></td>
<td><p class="First">2.4</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Percentages based on total subjects evaluated for each laboratory parameter.</p>
<p>Trial in Treatmentâ€‘Naive Subjects: Treatmentâ€‘Emergent Adverse Events:<span class="Italics"></span>Treatmentâ€‘emergent adverse events, regardless of causality, from Trial A4001026, a doubleâ€‘blind, comparative, controlled trial in which 721Â treatmentâ€‘naive subjects received SELZENTRY 300Â mg twice daily (NÂ =Â 360) or efavirenz (NÂ =Â 361) in combination with zidovudine/lamivudine for 96Â weeks, are summarized in Table 5. Selected events occurring in â‰¥2% of subjects and at a numerically higher rate in subjects treated with SELZENTRY are included; events that occurred at the same or higher rate on efavirenz are not displayed.</p>
<table>
<caption><span>Table 5. Percentage of Subjects With Selected Treatment-Emergent Adverse Events (All Causality) (â‰¥2% on SELZENTRY and at a higher rate compared with efavirenz) Trial A4001026 (96 Weeks)</span></caption>
<col span="1" width="52%">
<col span="1" width="34%">
<col span="1" width="30%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First">SELZENTRY 300Â mg Twice Daily + </p>
<p>Zidovudine/Lamivudine</p>
<p>(NÂ =Â 360)</p>
<p>%</p>
</td>
<td>
<p class="First">Efavirenz 600Â mg Once Daily + </p>
<p>Zidovudine/Lamivudine</p>
<p>(NÂ =Â 361)</p>
<p>%</p>
</td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemias</span> NEC</p></td>
<td><p class="First">8</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenias</span></p></td>
<td><p class="First">4</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Ear and Labyrinth Disorders</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">Ear disorders</span> NEC</p></td>
<td><p class="First">3</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, and <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span></p></td>
<td><p class="First">10</p></td>
<td><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First">Gastrointestinal atonic and hypomotility disorders NEC</p></td>
<td><p class="First">9</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">Gastrointestinal signs and symptoms NEC</p></td>
<td><p class="First">3</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Body temperature perception </p></td>
<td><p class="First">3</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span> </span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td><p class="First">13</p></td>
<td><p class="First">9</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">Herpes infection</span></p></td>
<td><p class="First">7</p></td>
<td><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td><p class="First">32</p></td>
<td><p class="First">30</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Bacterial infections</span> NEC</p></td>
<td><p class="First">6</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span>/<span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span></p></td>
<td><p class="First">5</p></td>
<td><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First">Lower respiratory tract and <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infections</span></p></td>
<td><p class="First">3</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Neisseria</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></p></td>
<td><p class="First">3</p></td>
<td><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea infections</span></p></td>
<td><p class="First">4</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span> NEC</p></td>
<td><p class="First">3</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Joint-related signs and symptoms</p></td>
<td><p class="First">6</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Memory loss</span> (excluding <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>)</p></td>
<td><p class="First">3</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesias</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesias</span> </p></td>
<td><p class="First">4</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Renal and Urinary Disorders</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Bladder and urethral symptoms</p></td>
<td><p class="First">4</p></td>
<td><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Erection and ejaculation conditions and disorders</p></td>
<td><p class="First">3</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Upper respiratory tract signs and symptoms</p></td>
<td><p class="First">9</p></td>
<td><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Skin and Subcutaneous Disorders</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acnes</span></p></td>
<td><p class="First">3</p></td>
<td><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecias</span></p></td>
<td><p class="First">2</p></td>
<td><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">Lipodystrophies</p></td>
<td><p class="First">4</p></td>
<td><p class="First">3</p></td>
</tr>
<tr class="Last">
<td><p class="First">Nail and nail bed conditions (excluding <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>)</p></td>
<td><p class="First">6</p></td>
<td><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Laboratory Abnormalities:</span></p>
<a name="_Refid_29d5b315-59df-49af-be3b-e612357a7"></a><table>
<caption><span>Table 6. Maximum Shift in Laboratory Test Values (Without Regard to Baseline) Incidence â‰¥2% of Grade 3-4 Abnormalities (ACTG Criteria) Trial A4001026 (96 Weeks)</span></caption>
<col span="1" width="37%">
<col span="1" width="14%">
<col span="1" width="25%">
<col span="1" width="25%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Laboratory Parameter Preferred Term</p></td>
<td><p class="First">Limit</p></td>
<td>
<p class="First">SELZENTRY</p>
<p>300 mg Twice Daily +</p>
<p>Zidovudine/Lamivudine<br>(NÂ =Â 353)<span class="Sup">a</span></p>
<p>%</p>
</td>
<td>
<p class="First">Efavirenz</p>
<p>600 mg Once Daily+</p>
<p>Zidovudine/Lamivudine<br>(NÂ =Â 350)<span class="Sup">a</span></p>
<p>%</p>
</td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span></p></td>
<td><p class="First">&gt;5.0 x ULN</p></td>
<td><p class="First">4.0</p></td>
<td><p class="First">4.0</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span></p></td>
<td><p class="First">&gt;5.0 x ULN</p></td>
<td><p class="First">3.9</p></td>
<td><p class="First">4.0</p></td>
</tr>
<tr>
<td><p class="First">Creatine kinase</p></td>
<td></td>
<td><p class="First">3.9</p></td>
<td><p class="First">4.8</p></td>
</tr>
<tr>
<td><p class="First">Amylase</p></td>
<td><p class="First">&gt;2.0 x ULN</p></td>
<td><p class="First">4.3</p></td>
<td><p class="First">6.0</p></td>
</tr>
<tr>
<td><p class="First">Absolute neutrophil count</p></td>
<td><p class="First">&lt;750/mm<span class="Sup">3</span></p></td>
<td><p class="First">5.7</p></td>
<td><p class="First">4.9</p></td>
</tr>
<tr class="Last">
<td><p class="First">Hemoglobin</p></td>
<td><p class="First">&lt;7.0Â g/dL</p></td>
<td><p class="First">2.9</p></td>
<td><p class="First">2.3</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>NÂ =Â Total number of subjects evaluable for laboratory abnormalities. </p>
<p>Percentages based on total subjects evaluated for each laboratory parameter. If the same subject in a given treatment group had &gt;1Â occurrence of the same abnormality, only the most severe is counted.</p>
<p><span class="Underline">Less Common Adverse Events in Clinical Trials:</span> The following adverse events occurred in &lt;2% of subjects treated with SELZENTRY. These events have been included because of their seriousness and either increased frequency on SELZENTRY or are potential risks due to the mechanism of action. Events attributed to the patientâ€™s underlying <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> are not listed.</p>
<p><span class="Italics">Blood and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Marrow depression</span> and <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable angina</span>, acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="316995" conceptname="Coronary occlusion">coronary artery occlusion</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>.</p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">Hepatic cirrhosis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="199837" conceptname="Portal vein thrombosis">portal vein thrombosis</span>, hypertransaminasemia, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:</span> <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span>, <span class="product-label-link" type="condition" conceptid="76508" conceptname="Infective myositis">infective myositis</span>, <span class="product-label-link" type="condition" conceptid="433403" conceptname="Viral meningitis">viral meningitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, treponema <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, <span class="Italics">Clostridium</span> difficile <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.</p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">Myositis</span>, <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, blood CK increased.</p>
<p><span class="Italics">Neoplasms Benign, Malignant, and Unspecified (Including <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cysts</span> and <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">Polyps</span>):</span> Abdominal neoplasm, anal cancer, basal cell carcinoma, Bowenâ€™s disease, <span class="product-label-link" type="condition" conceptid="4321680" conceptname="Cholangiocarcinoma">cholangiocarcinoma</span>, diffuse large B-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> to liver, esophageal carcinoma, nasopharyngeal carcinoma, squamous cell carcinoma, squamous cell carcinoma of skin, <span class="product-label-link" type="condition" conceptid="4130375" conceptname="Neoplasm of tongue">tongue neoplasm</span> (malignant stage unspecified), anaplastic large cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> T- and null-cell types, bile duct neoplasms malignant, endocrine neoplasms malignant and unspecified.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (excluding congenital), <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial palsy</span>, <span class="product-label-link" type="condition" conceptid="4300870" conceptname="Hemianopia">hemianopia</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>The following events have been identified during post-approval use of SELZENTRY and are not listed above. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to estimate their frequency or establish a causal relationship to exposure to SELZENTRY.</p>
<p>Skin and Subcutaneous Tissue Disorders: Stevensâ€‘Johnson syndrome, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN).</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>Maraviroc is a substrate of CYP3A and P-glycoprotein (P-gp) and hence its pharmacokinetics are likely to be modulated by inhibitors and inducers of these enzymes/transporters. Therefore, a dose adjustment may be required when maraviroc is coadministered with those drugs <span class="Italics">[see Dosage and Administration (2)]</span>.</p>
<p>Concomitant use of maraviroc and St. John's wort (<span class="Italics">Hypericum perforatum</span>) or products containing St. John's wort is not recommended. Coadministration of maraviroc with St. John's wort is expected to substantially decrease maraviroc concentrations and may result in suboptimal levels of maraviroc and lead to loss of virologic response and possible resistance to maraviroc.</p>
<p>For additional drug interaction information, see <span class="Italics">Clinical Pharmacology (12.3)</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<a href="http://"></a><p class="First"></p>
<p><span class="Underline">Pregnancy Category B:</span> The incidence of fetal variations and malformations was not increased in embryofetal toxicity studies performed with maraviroc in rats at exposures (AUC) approximately 20-fold higher and in rabbits at approximately 5-fold higher than human exposures at the recommended daily dose (up to 1,000Â mg/kg/day in rats and 75Â mg/kg/day in rabbits). During the pre- and postnatal development studies in the offspring, development of the offspring, including fertility and reproductive performance, was not affected by the maternal administration of maraviroc.</p>
<p>However, there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, SELZENTRY should be used during pregnancy only if clearly needed.</p>
<p><span class="Underline">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to SELZENTRY and other antiretroviral agents, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p><span class="Bold"> The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.</span> Studies in lactating rats indicate that maraviroc is extensively secreted into rat milk. It is not known whether maraviroc is secreted into human milk. Because of the potential for both HIV transmission and serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed if they are receiving SELZENTRY.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>The pharmacokinetics, safety and efficacy of maraviroc in patients younger than 16Â years have not been established. Therefore, maraviroc should not be used in this patient population.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Â  There were insufficient numbers of subjects aged 65 and over in the clinical trials to determine whether they respond differently from younger subjects. In general, caution should be exercised when administering SELZENTRY in elderly patients, also reflecting the greater frequency of decreased hepatic and renal function, of concomitant disease and other drug therapy. </p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Â  Recommended doses of SELZENTRY for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (CrClÂ â‰¤80Â mL/min) are based on the results of a pharmacokinetic trial conducted in healthy subjects with various degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The pharmacokinetics of maraviroc in subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was similar to that in subjects with normal renal function <span class="Italics">[see Clinical Pharmacology (12.3)]</span>. A limited number of subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> in the Phase 3 clinical trials (nÂ =Â 131 and nÂ =Â 12, respectively) received the same dose of SELZENTRY as that administered to subjects with normal renal function. In these subjects there was no apparent difference in the adverse event profile for maraviroc compared with subjects with normal renal function.</p>
<p> If patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD not receiving a concomitant potent CYP3A inhibitor or inducer experience any symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> while taking SELZENTRY 300Â mg twice daily, the dose should be reduced to 150Â mg twice daily. No trials have been performed in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD co-treated with potent CYP3A inhibitors or inducers. Hence, no dose of SELZENTRY can be recommended, and SELZENTRY is contraindicated for these patients <span class="Italics">[see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.2), Clinical Pharmacology (12.3)]</span>. </p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p> Maraviroc is principally metabolized by the liver; therefore, caution should be exercised when administering this drug to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, because maraviroc concentrations may be increased. Maraviroc concentrations are higher when SELZENTRY 150Â mg is administered with a potent CYP3A inhibitor compared with following administration of 300Â mg without a CYP3A inhibitor, so patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> who receive SELZENTRY 150Â mg with a potent CYP3A inhibitor should be monitored closely for maraviroc-associated adverse events. Maraviroc has not been studied in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)]</span>.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p> Population pharmacokinetic analysis of pooled Phase 1/2a data indicated gender (female: nÂ =Â 96, 23.2% of the total population) does not affect maraviroc concentrations. Dosage adjustment based on gender is not necessary.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p> Population pharmacokinetic analysis of pooled Phase 1/2a data indicated exposure was 26.5% higher in Asians (NÂ =Â 95) as compared with non-Asians (nÂ =Â 318). However, a trial designed to evaluate pharmacokinetic differences between Caucasians (nÂ =Â 12) and Singaporeans (nÂ =Â 12) showed no difference between these 2Â populations. No dose adjustment based on race is needed.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<a href="http://"></a><p class="First"></p>
<p> The highest dose administered in clinical trials was 1,200Â mg. The dose-limiting adverse event was <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, which was observed at 600Â mg. While the recommended dose for SELZENTRY in patients receiving a CYP3A inducer without a CYP3A inhibitor is 600Â mg twice daily, this dose is appropriate due to enhanced metabolism. </p>
<p> Prolongation of the QT interval was seen in dogs and monkeys at plasma concentrations 6 and 12Â times, respectively, those expected in humans at the intended exposure of 300Â mg equivalents twice daily. However, no significant QT prolongation was seen in the trials in treatment-experienced subjects with HIV using the recommended doses of maraviroc or in a specific pharmacokinetic trial to evaluate the potential of maraviroc to prolong the QT interval <span class="Italics">[see</span><span class="Italics"> Clinical Pharmacology (12.3)]</span>.</p>
<p> There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with maraviroc. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should consist of general supportive measures including keeping the patient in a supine position, careful assessment of patient vital signs, blood pressure, and ECG.</p>
<p> If indicated, elimination of unabsorbed active maraviroc should be achieved by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since maraviroc is moderately protein-bound, dialysis may be beneficial in removal of this medicine.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<a href="http://"></a><p class="First"></p>
<p>SELZENTRY (maraviroc) is a selective, slowly reversible, small molecule antagonist of the interaction between human CCR5 and HIV-1 gp120. Blocking this interaction prevents CCR5-tropic HIV-1 entry into cells.</p>
<p>SELZENTRY is available as film-coated tablets for oral administration containing either 150 or 300Â mg of maraviroc and the following inactive ingredients: dibasic calcium phosphate (anhydrous), magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The film coat (Opadry<span class="Sup">Â®</span> II Blue [85G20583]) contains FD&amp;C blue #2 aluminum lake, soya lecithin, polyethylene glycol (macrogol 3350), polyvinyl alcohol, talc, and titanium dioxide.</p>
<p>Maraviroc is chemically described as 4,4-difluoro-<span class="Italics">N</span>-{(1<span class="Italics">S</span>)-3<span class="Italics">-</span>[<span class="Italics">exo</span>-3-(3-isopropyl-5-methyl-4<span class="Italics">H</span>-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}cyclohexanecarboxamide.</p>
<p>The molecular formula is C<span class="Sub">29</span>H<span class="Sub">41</span>F<span class="Sub">2</span>N<span class="Sub">5</span>O and the structural formula is:</p>
<div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=74fba35e-931e-44d8-97e0-d243bb687a71&amp;name=MM1.jpg"></div>
<p>Maraviroc is a white- to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-colored powder with a molecular weight of 513.67. It is highly soluble across the physiological pH range (pH 1.0 to 7.5).</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<p>Maraviroc is an antiviral drug <span class="Italics">[see Clinical Pharmacology (12.4)]</span>.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p><span class="Underline">Exposure-Response Relationship in Treatment-Experienced Subjects:</span> The relationship between maraviroc, modeled plasma trough concentration (C<span class="Sub">min</span>) (1 to 9 samples per patient taken on up to 7Â visits), and virologic response was evaluated in 973Â treatment-experienced HIV-1-infected subjects with varied optimized background antiretroviral regimens in Trials A4001027 and A4001028. The C<span class="Sub">min</span>, baseline viral load, baseline CD4<span class="Sup">+</span> cell count, and overall sensitivity score (OSS) were found to be important predictors of virologic success (defined as viral load &lt;400Â copies/mL at 24Â weeks). Table 7 illustrates the proportions of subjects with virologic success (%) within each C<span class="Sub">min</span> quartile for 150-mg twice-daily and 300-mg twice-daily groups.</p>
<a name="_Refid_c1cd9e0c-445c-4aae-acf0-a7d150054"></a><table>
<caption><span>Table 7. Treatment-Experienced Subjects With Virologic Success by C<span class="Sub">min</span> Quartile (Q1-Q4)</span></caption>
<col span="1" width="10%">
<col span="1" width="6%">
<col span="1" width="14%">
<col span="1" width="34%">
<col span="1" width="5%">
<col span="1" width="14%">
<col span="1" width="34%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First">150Â mg Twice Daily<br>(With CYP3A Inhibitors)</p></td>
<td><p class="First">300Â mg Twice Daily<br>(Without CYP3A Inhibitors)</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">n</p></td>
<td><p class="First">Median C<span class="Sub">min</span></p></td>
<td><p class="First">% Subjects With Virologic Success</p></td>
<td><p class="First">n</p></td>
<td><p class="First">Median C<span class="Sub">min</span></p></td>
<td><p class="First">% Subjects With Virologic Success</p></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td><p class="First">160</p></td>
<td><p class="First">-</p></td>
<td><p class="First">30.6</p></td>
<td><p class="First">35</p></td>
<td><p class="First">-</p></td>
<td><p class="First">28.6</p></td>
</tr>
<tr>
<td><p class="First">Q1</p></td>
<td><p class="First">78</p></td>
<td><p class="First">33</p></td>
<td><p class="First">52.6</p></td>
<td><p class="First">22</p></td>
<td><p class="First">13</p></td>
<td><p class="First">50.0</p></td>
</tr>
<tr>
<td><p class="First">Q2</p></td>
<td><p class="First">77</p></td>
<td><p class="First">87</p></td>
<td><p class="First">63.6</p></td>
<td><p class="First">22</p></td>
<td><p class="First">29</p></td>
<td><p class="First">68.2</p></td>
</tr>
<tr>
<td><p class="First">Q3</p></td>
<td><p class="First">78</p></td>
<td><p class="First">166</p></td>
<td><p class="First">78.2</p></td>
<td><p class="First">22</p></td>
<td><p class="First">46</p></td>
<td><p class="First">63.6</p></td>
</tr>
<tr class="Last">
<td><p class="First">Q4</p></td>
<td><p class="First">78</p></td>
<td><p class="First">279</p></td>
<td><p class="First">74.4</p></td>
<td><p class="First">22</p></td>
<td><p class="First">97</p></td>
<td><p class="First">68.2</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Exposure-Response Relationship in Treatment-Naive Subjects:</span> The relationship between maraviroc, modeled plasma trough concentration (C<span class="Sub">min</span>) (1 to 12 samples per patient taken on up to 8 visits), and virologic response was evaluated in 294Â treatment-naive HIV-1-infected subjects receiving maraviroc 300 mg twice daily in combination with zidovudine/lamivudine in Trial A4001026. Table 8 illustrates the proportion (%) of subjects with virologic success &lt;50 copies/mL at 48Â weeks within each C<span class="Sub">min</span> quartile for the 300-mg twice-daily dose.</p>
<a name="_Refid_17c8404e-a0af-4e51-a228-10593f9ec"></a><table>
<caption><span>Table 8. Treatment-Naive Subjects With Virologic Success by C<span class="Sub">min</span> Quartile (Q1-Q4)</span></caption>
<col span="1" width="5%">
<col span="1" width="5%">
<col span="1" width="14%">
<col span="1" width="35%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First">300Â mg Twice Daily </p></td>
</tr>
<tr>
<td></td>
<td><p class="First">n</p></td>
<td><p class="First">Median C<span class="Sub">min</span></p></td>
<td><p class="First">% Subjects With Virologic Success</p></td>
</tr>
<tr>
<td><p class="First">Q1</p></td>
<td><p class="First">75</p></td>
<td><p class="First">23</p></td>
<td><p class="First">57.3</p></td>
</tr>
<tr>
<td><p class="First">Q2</p></td>
<td><p class="First">72</p></td>
<td><p class="First">39</p></td>
<td><p class="First">72.2</p></td>
</tr>
<tr>
<td><p class="First">Q3</p></td>
<td><p class="First">73</p></td>
<td><p class="First">56</p></td>
<td><p class="First">74.0</p></td>
</tr>
<tr class="Last">
<td><p class="First">Q4</p></td>
<td><p class="First">74</p></td>
<td><p class="First">81</p></td>
<td><p class="First">83.8</p></td>
</tr>
</tbody>
</table>
<p>Eighteen of 75 (24%) subjects in Q1 had no measurable maraviroc concentration on at least one occasion versus 1 of 73 and 1 of 74 in Q3 and Q4, respectively.</p>
<p><span class="Underline">Effects on Electrocardiogram:</span> A placebo-controlled, randomized, crossover trial to evaluate the effect on the QT interval of healthy male and female volunteers was conducted with 3 single oral doses of maraviroc and moxifloxacin. The placebo-adjusted mean maximum (upper 1-sided 95% CI) increases in QTc from baseline after 100, 300, and 900 mg of maraviroc were â€“2 (0), -1 (1), and 1 (3) msec, respectively, and 13 (15) msec for moxifloxacin 400Â mg. No subject in any group had an increase in QTc of â‰¥60Â msec from baseline. No subject experienced an interval exceeding the potentially clinically relevant threshold of 500Â msec.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p><span class="Bold">Table 9.</span><span class="Bold"> Mean Maraviroc Pharmacokinetic Parameters</span></p>
<table>
<col span="1" width="28%">
<col span="1" width="26%">
<col span="1" width="6%">
<col span="1" width="13%">
<col span="1" width="11%">
<col span="1" width="13%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Patient Population</p></td>
<td><p class="First">Maraviroc Dose</p></td>
<td><p class="First">N</p></td>
<td><p class="First">AUC<span class="Sub">12</span> (ng.hr/mL)</p></td>
<td><p class="First">C<span class="Sub">max</span> (ng/mL)</p></td>
<td><p class="First">C<span class="Sub">min</span> (ng/mL)</p></td>
</tr>
<tr>
<td><p class="First">Healthy volunteers (Phase 1) </p></td>
<td><p class="First">300Â mg twice daily </p></td>
<td><p class="First">64</p></td>
<td><p class="First">2,908</p></td>
<td><p class="First">888</p></td>
<td><p class="First">43.1</p></td>
</tr>
<tr>
<td><p class="First">Asymptomatic HIV subjects (Phase 2a)</p></td>
<td><p class="First">300Â mg twice daily </p></td>
<td><p class="First">8</p></td>
<td><p class="First">2,550</p></td>
<td><p class="First">618</p></td>
<td><p class="First">33.6</p></td>
</tr>
<tr>
<td><p class="First">Treatment-experienced HIV subjects (Phase 3)<span class="Sup">a</span></p></td>
<td><p class="First">300Â mg twice daily</p></td>
<td><p class="First">94</p></td>
<td><p class="First">1,513</p></td>
<td><p class="First">266</p></td>
<td><p class="First">37.2 </p></td>
</tr>
<tr>
<td>
<p class="First">150Â mg twice daily </p>
<p>(+ CYP3A inhibitor)</p>
</td>
<td><p class="First">375</p></td>
<td><p class="First">2,463</p></td>
<td><p class="First">332</p></td>
<td><p class="First">101</p></td>
</tr>
<tr class="Last">
<td><p class="First">Treatment-naive HIV subjects (Phase 2b/3)<span class="Sup">a</span></p></td>
<td><p class="First">300Â mg twice daily</p></td>
<td><p class="First">344</p></td>
<td><p class="First">1,865</p></td>
<td><p class="First">287</p></td>
<td><p class="First">60</p></td>
</tr>
</tbody>
</table>Â <span class="Sup">a</span>The estimated exposure is lower compared with other trials possibly due to sparse sampling, food effect, compliance, and concomitant medications.<p>Absorption: Peak maraviroc plasma concentrations are attained 0.5 to 4Â hours following single oral doses of 1 to 1,200Â mg administered to uninfected volunteers. The pharmacokinetics of oral maraviroc are not dose proportional over the dose range. </p>
<p>The absolute bioavailability of a 100â€‘mg dose is 23% and is predicted to be 33% at 300Â mg. Maraviroc is a substrate for the efflux transporter P-gp.</p>
<p>Effect of Food on Oral Absorption: Coadministration of a 300â€‘mg tablet with a highâ€‘fat breakfast reduced maraviroc C<span class="Sub">max</span> and AUC by 33% in healthy volunteers. There were no food restrictions in the trials that demonstrated the efficacy and safety of maraviroc <span class="Italics">[see Clinical Studies (14)]. </span>Therefore, maraviroc can be taken with or without food at the recommended dose <span class="Italics">[see Dosage and Administration (2)]</span>.</p>
<p>Distribution: Maraviroc is bound (approximately 76%) to human plasma proteins, and shows moderate affinity for albumin and alphaâ€‘1 acid glycoprotein. The volume of distribution of maraviroc is approximately 194Â L. </p>
<p>Metabolism: Trials in humans and in vitro studies using human liver microsomes and expressed enzymes have demonstrated that maraviroc is principally metabolized by the cytochrome P450 system to metabolites that are essentially inactive against HIVâ€‘1. In vitro studies indicate that CYP3A is the major enzyme responsible for maraviroc metabolism. In vitro studies also indicate that polymorphic enzymes CYP2C9, CYP2D6, and CYP2C19 do not contribute significantly to the metabolism of maraviroc.</p>
<p>Maraviroc is the major circulating component (~42% drugâ€‘related radioactivity) following a single oral dose of 300Â mg [<span class="Sup">14</span>C]-maraviroc. The most significant circulating metabolite in humans is a secondary amine (~22% radioactivity) formed by Nâ€‘dealkylation. This polar metabolite has no significant pharmacological activity. Other metabolites are products of monoâ€‘oxidation and are only minor components of plasma drugâ€‘related radioactivity.</p>
<p>Excretion: The terminal halfâ€‘life of maraviroc following oral dosing to steady state in healthy subjects was 14 to 18Â hours. A <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance/excretion trial was conducted using a single 300â€‘mg dose of <span class="Sup">14</span>C-labeled maraviroc. Approximately 20% of the radiolabel was recovered in the urine and 76% was recovered in the feces over 168Â hours. Maraviroc was the major component present in urine (mean of 8% dose) and feces (mean of 25% dose). The remainder was excreted as metabolites.</p>
<p><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Maraviroc is primarily metabolized and eliminated by the liver. A trial compared the pharmacokinetics of a single 300â€‘mg dose of SELZENTRY in subjects with mild (Childâ€‘Pugh Class A, nÂ =Â 8), and moderate (Childâ€‘Pugh Class B, nÂ =Â 8) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to pharmacokinetics in healthy subjects (nÂ =Â 8). The mean C<span class="Sub">max</span> and AUC were 11% and 25% higher, respectively, for subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and 32% and 46% higher, respectively, for subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with subjects with normal hepatic function. These changes do not warrant a dose adjustment. Maraviroc concentrations are higher when SELZENTRY 150Â mg is administered with a potent CYP3A inhibitor compared with following administration of 300Â mg without a CYP3A inhibitor, so patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> who receive SELZENTRY 150Â mg with a potent CYP3A inhibitor should be monitored closely for maravirocâ€‘associated adverse events. The pharmacokinetics of maraviroc have not been studied in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: A trial compared the pharmacokinetics of a single 300â€‘mg dose of SELZENTRY in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt;30Â mL/min, nÂ =Â 6) and ESRD (nÂ =Â 6) to healthy volunteers (nÂ =Â 6). Geometric mean ratios for maraviroc C<span class="Sub">max</span> and AUC<span class="Sub">inf</span> were 2.4â€‘fold and 3.2â€‘fold higher, respectively, for subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and 1.7â€‘fold and 2.0â€‘fold higher, respectively, for subjects with ESRD as compared with subjects with normal renal function in this trial. Hemodialysis had a minimal effect on maraviroc clearance and exposure in subjects with ESRD. Exposures observed in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and ESRD were within the range observed in previous 300â€‘mg singleâ€‘dose trials of SELZENTRY in healthy volunteers with normal renal function. However, maraviroc exposures in the subjects with normal renal function in this trial were 50% lower than that observed in previous trials. Based on the results of this trial, no dose adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> receiving SELZENTRY without a potent CYP3A inhibitor or inducer. However, if patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or ESRD experience any symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> while taking SELZENTRY 300Â mg twice daily, their dose should be reduced to 150Â mg twice daily <span class="Italics">[see Dosage and Administration (2.2); Warnings and Precautions (5.2)]</span>.</p>
<p>In addition, the trial compared the pharmacokinetics of multipleâ€‘dose SELZENTRY in combination with saquinavir/ritonavir 1,000/100Â mg twice daily (a potent CYP3A inhibitor combination) for 7Â days in subjects with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &gt;50 and 80Â mL/min, nÂ =Â 6) and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr 30 and 50Â mL/min, nÂ =Â 6) to healthy volunteers with normal renal function (nÂ =Â 6). Subjects received 150Â mg of SELZENTRY at different dose frequencies (healthy volunteers â€“ every 12Â hours; mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> â€“ every 24Â hours; moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> â€“ every 48Â hours). Compared with healthy volunteers (dosed every 12Â hours), geometric mean ratios for maraviroc AUC<span class="Sub">tau</span>, C<span class="Sub">max</span>, and C<span class="Sub">min</span> were 50% higher, 20% higher, and 43% lower, respectively, for subjects with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (dosed every 24Â hours). Geometric mean ratios for maraviroc AUC<span class="Sub">tau</span>, C<span class="Sub">max</span>, and C<span class="Sub">min</span> were 16% higher, 29% lower, and 85% lower, respectively, for subjects with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (dosed every 48Â hours) compared with healthy volunteers (dosed every 12Â hours). Based on the data from this trial, no adjustment in dose is recommended for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Dosage and Administration (2.2)]</span>. </p>
<p><span class="Italics"></span>Effect of Concomitant Drugs on the Pharmacokinetics of Maraviroc: Maraviroc is a substrate of CYP3A and P-gp and hence its pharmacokinetics are likely to be modulated by inhibitors and inducers of these enzymes/transporters. The CYP3A/P-gp inhibitors ketoconazole, lopinavir/ritonavir, ritonavir, darunavir/ritonavir, saquinavir/ritonavir, and atazanavir Â± ritonavir all increased the C<span class="Sub">max </span>and AUC of maraviroc (see Table 10). The CYP3A inducers rifampin, etravirine, and efavirenz decreased the C<span class="Sub">max </span>and AUC of maraviroc (see Table 10).</p>
<p>Tipranavir/ritonavir (net CYP3A inhibitor/P-gp inducer) did not affect the steadyâ€‘state pharmacokinetics of maraviroc (see Table 10). Cotrimoxazole and tenofovir did not affect the pharmacokinetics of maraviroc. </p>
<p><span class="Bold">Table 10.</span><span class="Bold"> Effect of Coadministered Agents on the Pharmacokinetics of Maraviroc</span></p>
<table>
<col span="1" width="28%">
<col span="1" width="6%">
<col span="1" width="1%">
<col span="1" width="15%">
<col span="1" width="15%">
<col span="1" width="1%">
<col span="1" width="17%">
<col span="1" width="18%">
<tbody class="Headless">
<tr class="First">
<td>
<p class="First"><span class="Bold">Coadministered Drug</span></p>
<p><span class="Bold">and Dose</span></p>
</td>
<td><p class="First"><span class="Bold">N</span></p></td>
<td><p class="First"><span class="Bold">Dose of SELZENTRY</span></p></td>
<td>
<p class="First"><span class="Bold">Ratio (90% CI) of Maraviroc Pharmacokinetic Parameters With/Without Coadministered Drug</span></p>
<p><span class="Bold">(No Effect = 1.00)</span></p>
</td>
</tr>
<tr>
<td><p class="First">C<span class="Sub">min</span></p></td>
<td><p class="First">AUC<span class="Sub">tau</span></p></td>
<td><p class="First">C<span class="Sub">max</span></p></td>
</tr>
<tr><td><p class="First"><span class="Bold">CYP3A and/or P-gp Inhibitors</span></p></td></tr>
<tr>
<td>
<p class="First">Ketoconazole</p>
<p>400Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">100Â mg b.i.d.</p></td>
<td>
<p class="First">3.75</p>
<p>(3.01, 4.69)</p>
</td>
<td>
<p class="First">5.00</p>
<p>(3.98, 6.29)</p>
</td>
<td>
<p class="First">3.38</p>
<p>(2.38, 4.78)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Ritonavir</p>
<p>100Â mg b.i.d.</p>
</td>
<td><p class="First">8</p></td>
<td><p class="First">100Â mg b.i.d.</p></td>
<td>
<p class="First">4.55</p>
<p>(3.37, 6.13)</p>
</td>
<td>
<p class="First">2.61</p>
<p>(1.92, 3.56)</p>
</td>
<td>
<p class="First">1.28</p>
<p>(0.79, 2.09)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Saquinavir (soft gel capsules) /ritonavir</p>
<p>1,000Â mg/100Â mg b.i.d.</p>
</td>
<td><p class="First">11</p></td>
<td><p class="First">100Â mg b.i.d.</p></td>
<td>
<p class="First">11.3</p>
<p>(8.96, 14.1)</p>
</td>
<td>
<p class="First">9.77</p>
<p>(7.87, 12.14)</p>
</td>
<td>
<p class="First">4.78</p>
<p>(3.41, 6.71)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Lopinavir/ritonavir</p>
<p>400Â mg/100Â mg b.i.d.</p>
</td>
<td><p class="First">11</p></td>
<td><p class="First">300Â mg b.i.d.</p></td>
<td>
<p class="First">9.24</p>
<p>(7.98, 10.7)</p>
</td>
<td>
<p class="First">3.95</p>
<p>(3.43, 4.56)</p>
</td>
<td>
<p class="First">1.97</p>
<p>(1.66, 2.34)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Atazanavir</p>
<p>400Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">300Â mg b.i.d.</p></td>
<td>
<p class="First">4.19</p>
<p>(3.65, 4.80)</p>
</td>
<td>
<p class="First">3.57</p>
<p>(3.30, 3.87)</p>
</td>
<td>
<p class="First">2.09</p>
<p>(1.72, 2.55)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Atazanavir/ritonavir</p>
<p>300Â mg/100Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">300Â mg b.i.d.</p></td>
<td>
<p class="First">6.67</p>
<p>(5.78, 7.70)</p>
</td>
<td>
<p class="First">4.88</p>
<p>(4.40, 5.41)</p>
</td>
<td>
<p class="First">2.67</p>
<p>(2.32, 3.08)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Darunavir/ritonavir</p>
<p>600 mg/100Â mg b.i.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">150Â mg b.i.d.</p></td>
<td>
<p class="First">8.00</p>
<p>(6.35, 10.1)</p>
</td>
<td>
<p class="First">4.05</p>
<p>2.94, 5.59</p>
</td>
<td>
<p class="First">2.29</p>
<p>(1.46, 3.59)</p>
</td>
</tr>
<tr><td><p class="First"><span class="Bold">CYP3A and/or P-gp Inducers</span></p></td></tr>
<tr>
<td>
<p class="First">Efavirenz </p>
<p>600Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">100Â mg b.i.d.</p></td>
<td>
<p class="First">0.55</p>
<p>(0.43, 0.72)</p>
</td>
<td>
<p class="First">0.552</p>
<p>(0.492, 0.620)</p>
</td>
<td>
<p class="First">0.486</p>
<p>(0.377, 0.626)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Efavirenz</p>
<p>600Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td>
<p class="First">200Â mg b.i.d.</p>
<p>(+ efavirenz):</p>
<p>100Â mg b.i.d. (alone)</p>
</td>
<td>
<p class="First">1.09</p>
<p>(0.89, 1.35)</p>
</td>
<td>
<p class="First">1.15</p>
<p>(0.98, 1.35)</p>
</td>
<td>
<p class="First">1.16</p>
<p>(0.87, 1.55)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Rifampicin</p>
<p>600Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">100Â mg b.i.d.</p></td>
<td>
<p class="First">0.22</p>
<p>(0.17, 0.28)</p>
</td>
<td>
<p class="First">0.368</p>
<p>(0.328, 0.413)</p>
</td>
<td>
<p class="First">0.335</p>
<p>(0.260, 0.431)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Rifampicin</p>
<p>600Â mg q.d.</p>
</td>
<td><p class="First">12</p></td>
<td>
<p class="First">200 mg b.i.d.</p>
<p>(+ rifampicin):</p>
<p>100 mg b.i.d. (alone)</p>
</td>
<td>
<p class="First">0.66</p>
<p>(0.54, 0.82)</p>
</td>
<td>
<p class="First">1.04</p>
<p>(0.89, 1.22)</p>
</td>
<td>
<p class="First">0.97</p>
<p>(0.72, 1.29)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Etravirine</p>
<p>200Â mg b.i.d.</p>
</td>
<td><p class="First">14</p></td>
<td><p class="First">300Â mg b.i.d.</p></td>
<td>
<p class="First">0.609</p>
<p>(0.525, 0.707)</p>
</td>
<td>
<p class="First">0.468</p>
<p>(0.381, 0.576)</p>
</td>
<td>
<p class="First">0.400</p>
<p>(0.282, 0.566)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Nevirapine<span class="Sup">a</span></p>
<p>200 mg b.i.d. <br>(+ lamivudine 150 mg b.i.d., tenofovir 300 mg q.d.)</p>
</td>
<td><p class="First">8</p></td>
<td>
<p class="First">300Â mg </p>
<p>single dose</p>
</td>
<td><p class="First">-</p></td>
<td>
<p class="First">1.01</p>
<p>(0.65, 1.55)</p>
</td>
<td>
<p class="First">1.54</p>
<p>(0.94, 2.51)</p>
</td>
</tr>
<tr><td><p class="First"><span class="Bold">CYP3A and/or P-gp Inhibitors and Inducers</span></p></td></tr>
<tr>
<td>
<p class="First">Lopinavir/ritonavir + efavirenz </p>
<p>400Â mg/100Â mg b.i.d. + 600Â mg q.d.</p>
</td>
<td><p class="First">11 </p></td>
<td><p class="First">300Â mg b.i.d.</p></td>
<td>
<p class="First">6.29</p>
<p>(4.72, 8.39)</p>
</td>
<td>
<p class="First">2.53</p>
<p>(2.24, 2.87)</p>
</td>
<td>
<p class="First">1.25</p>
<p>(1.01, 1.55)</p>
</td>
</tr>
<tr>
<td><p class="First">Saquinavir(soft gel capsules) /ritonavir + efavirenz 1,000Â mg/100Â mg b.i.d. + 600Â mg q.d.</p></td>
<td><p class="First">11</p></td>
<td><p class="First">100Â mg b.i.d.</p></td>
<td>
<p class="First">8.42</p>
<p>(6.46, 10.97)</p>
</td>
<td>
<p class="First">5.00</p>
<p>(4.26, 5.87)</p>
</td>
<td>
<p class="First">2.26</p>
<p>(1.64, 3.11)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Darunavir/ritonavir + etravirine </p>
<p>600Â mg/100Â mg b.i.d. + 200Â mg b.i.d.</p>
</td>
<td><p class="First">10</p></td>
<td><p class="First">150Â mg b.i.d.</p></td>
<td>
<p class="First">5.27</p>
<p>(4.51, 6.15)</p>
</td>
<td>
<p class="First">3.10</p>
<p>(2.57, 3.74)</p>
</td>
<td>
<p class="First">1.77</p>
<p>(1.20, 2.60)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Tipranavir/ritonavir</p>
<p>500Â mg/200Â mg b.i.d.</p>
</td>
<td><p class="First">12</p></td>
<td><p class="First">150Â mg b.i.d.</p></td>
<td>
<p class="First">1.80</p>
<p>(1.55, 2.09)</p>
</td>
<td>
<p class="First">1.02</p>
<p>(0.850, 1.23)</p>
</td>
<td>
<p class="First">0.86</p>
<p>(0.61, 1.21)</p>
</td>
</tr>
<tr><td><p class="First"><span class="Bold">Other</span></p></td></tr>
<tr class="Last">
<td>
<p class="First">Raltegravir </p>
<p>400 mg b.i.d.</p>
</td>
<td><p class="First">17</p></td>
<td><p class="First">300Â mg b.i.d.</p></td>
<td>
<p class="First">0.90</p>
<p>(0.85, 0.96)</p>
</td>
<td>
<p class="First">0.86</p>
<p>(0.80, 0.92)</p>
</td>
<td>
<p class="First">0.79</p>
<p>(0.67, 0.94)</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Compared with historical data.</p>
<p>Effect of Maraviroc on the Pharmacokinetics of Concomitant Drugs: Maraviroc is unlikely to inhibit the metabolism of coadministered drugs metabolized by the following cytochrome P enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A) because maraviroc did not inhibit activity of those enzymes at clinically relevant concentrations in vitro. Maraviroc does not induce CYP1A2 in vitro.</p>
<p>In vitro results suggest that maraviroc could inhibit P-gp in the gut. However, maraviroc did not significantly affect the pharmacokinetics of digoxin in vivo, indicating maraviroc may not significantly inhibit or induce P-gp clinically.</p>
<p>Drug interaction trials were performed with maraviroc and other drugs likely to be coadministered or commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> (see Table 10). Maraviroc had no effect on the pharmacokinetics of zidovudine or lamivudine. Maraviroc decreased the Cmin and AUC of raltegravir by 27% and 37%, respectively, which is not clinically significant. Maraviroc had no clinically relevant effect on the pharmacokinetics of midazolam, the oral contraceptives ethinylestradiol and levonorgestrel, no effect on the urinary 6Î²-hydroxycortisol/cortisol ratio, suggesting no induction of CYP3A in vivo. Maraviroc had no effect on the debrisoquine metabolic ratio (MR) at 300Â mg twice daily or less in vivo and did not cause inhibition of CYP2D6 in vitro until concentrations &gt;100Â ÂµM. However, there was 234% increase in debrisoquine MR on treatment compared with baseline at 600Â mg once daily, suggesting potential inhibition of CYP2D6 at higher dose.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p><span class="Underline">Mechanism of Action:</span> Maraviroc is a member of a therapeutic class called CCR5 co-receptor antagonists. Maraviroc selectively binds to the human chemokine receptor CCR5 present on the cell membrane, preventing the interaction of HIV-1 gp120 and CCR5 necessary for CCR5-tropic HIV-1 to enter cells.Â  CXCR4-tropic and dual-tropic HIV-1 entry is not inhibited by maraviroc.</p>
<p><span class="Underline">Antiviral Activity in Cell Culture:</span> Maraviroc inhibits the replication of CCR5-tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and primary isolates of HIV-1 in models of acute peripheral blood leukocyte <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The mean EC<span class="Sub">50</span> value (50% effective concentration) for maraviroc against HIV-1 group M isolates (subtypes A to J and circulating recombinant form AE) and group O isolates ranged from 0.1 to 4.5Â nM (0.05 to 2.3Â ng/mL) in cell culture.</p>
<p>When used with other antiretroviral agents in cell culture, the combination of maraviroc was not antagonistic with NNRTIs (delavirdine, efavirenz, and nevirapine), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), or protease inhibitors (amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir). Maraviroc was additive/synergistic with the HIV fusion inhibitor enfuvirtide. Maraviroc was not active against CXCR4-tropic and dual-tropic viruses (EC<span class="Sub">50</span> value &gt;10Â ÂµM). The antiviral activity of maraviroc against HIV-2 has not been evaluated.</p>
<p><span class="Italics">Resistance in Cell Culture:</span> HIV-1 variants with reduced susceptibility to maraviroc have been selected in cell culture, following serial passage of 2 CCR5-tropic viruses (CC1/85 and RU570). The maraviroc-resistant viruses remained CCR5-tropic with no evidence of a change from a CCR5-tropic virus to a CXCR4-using virus. Two amino acid residue substitutions in the V3-loop region of the HIV-1 envelope glycoprotein (gp160), A316T, and I323V (HXB2 numbering), were shown to be necessary for the maraviroc-resistant phenotype in the HIV-1 isolate CC1/85. In the RU570 isolate a 3-amino acid residue deletion in the V3 loop, Î”QAI (HXB2 positions 315 to 317), was associated with maraviroc resistance. The relevance of the specific gp120 mutations observed in maraviroc-resistant isolates selected in cell culture to clinical maraviroc resistance is not known. Maraviroc-resistant viruses were characterized phenotypically by concentration-response curves that did not reach 100% inhibition in phenotypic drug assays, rather than increases in EC<span class="Sub">50</span> values. </p>
<p><span class="Italics">Cross-Resistance in Cell Culture:</span> Maraviroc had antiviral activity against HIV-1 clinical isolates resistant to NNRTIs, NRTIs, PIs, and the fusion inhibitor enfuvirtide in cell culture (EC<span class="Sub">50</span> values ranged from 0.7 to 8.9Â nM (0.36 to 4.57Â ng/mL). Maraviroc-resistant viruses that emerged in cell culture remained susceptible to the enfuvirtide and the protease inhibitor saquinavir.</p>
<p><span class="Italics">Clinical Resistance:</span> Virologic failure on maraviroc can result from genotypic and phenotypic resistance to maraviroc, through outgrowth of undetected CXCR4-using virus present before maraviroc treatment (see <span class="Italics">Tropism</span> below), through resistance to background therapy drugs (Table 11), or due to low exposure to maraviroc <span class="Italics">[see Clinical Pharmacology (12.2)]</span>.</p>
<p><span class="Italics">Antiretroviral Treatment-Experienced Subjects (Trials A4001027 and A4001028):</span> Week 48 data from treatment-experienced subjects failing maraviroc-containing regimens with CCR5-tropic virus (nÂ =Â 58) have identified 22Â viruses that had decreased susceptibility to maraviroc characterized in phenotypic drug assays by concentration-response curves that did not reach 100% inhibition. Additionally, CCR5-tropic virus from 2 of these treatment-failure subjects had â‰¥3-fold shifts in EC<span class="Sub">50</span> values for maraviroc at the time of failure.</p>
<p>Fifteen of these viruses were sequenced in the gp120 encoding region and multiple amino acid substitutions with unique patterns in the heterogeneous V3 loop region were detected. Changes at either amino acid position 308 or 323 (HXB2 numbering) were seen in the V3 loop in 7 of the subjects with decreased maraviroc susceptibility. Substitutions outside the V3 loop of gp120 may also contribute to reduced susceptibility to maraviroc.</p>
<p><span class="Italics">Antiretroviral Treatment-Naive Subjects (Trial A4001026):</span> Treatment-naive subjects receiving SELZENTRY had more virologic failures and more treatment-emergent resistance to the background regimen drugs compared with those receiving efavirenz (Table 11).</p>
<a name="_Refid_2aaeba04-be08-484e-92a8-c3e305d52"></a><table>
<caption><span>Table 11. Development of Resistance to Maraviroc or Efavirenz and Background Drugs in Antiretroviral Treatment-Naive Trial A4001026 for Patients with CCR5-Tropic Virus at Screening Using Enhanced Sensitivity TROFILE<span class="Sup">Â®</span> Assay</span></caption>
<col span="1" width="74%">
<col span="1" width="12%">
<col span="1" width="11%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td><p class="First">Maraviroc</p></td>
<td><p class="First">Efavirenz</p></td>
</tr>
<tr>
<td><p class="First">Total N in dataset (as-treated)</p></td>
<td><p class="First">273</p></td>
<td><p class="First">241</p></td>
</tr>
<tr>
<td><p class="First">Total virologic failures (as-treated)</p></td>
<td><p class="First">85 (31%)</p></td>
<td><p class="First">56 (23%)</p></td>
</tr>
<tr>
<td><p class="First">Evaluable virologic failures with post baseline genotypic and phenotypic data</p></td>
<td><p class="First">73</p></td>
<td><p class="First">43</p></td>
</tr>
<tr>
<td><ul><li>Lamivudine resistance</li></ul></td>
<td><p class="First">39 (53%)</p></td>
<td><p class="First">13 (30%)</p></td>
</tr>
<tr>
<td><ul><li>Zidovudine resistance</li></ul></td>
<td><p class="First">2 (3%)</p></td>
<td><p class="First">0</p></td>
</tr>
<tr>
<td><ul><li>Efavirenz resistance</li></ul></td>
<td><p class="First">--</p></td>
<td><p class="First">23 (53%)</p></td>
</tr>
<tr class="Last">
<td><ul><li>Phenotypic resistance to maraviroc<span class="Sup">a</span>
</li></ul></td>
<td><p class="First">19 (26 % )</p></td>
<td></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Includes subjects failing with CXCR4- or dual/mixed-tropism because these viruses are not intrinsically susceptible to maraviroc.</p>
<p>In an as-treated analysis of treatment-naive subjects at 96 weeks, 32 subjects failed a maraviroc-containing regimen with CCR5-tropic virus and had a tropism result at failure; 7 of these subjects had evidence of maraviroc phenotypic resistance defined as concentration-response curves that did not reach 95% inhibition. One additional subject had a â‰¥3-fold shift in the EC<span class="Sub">50</span> value for maraviroc at the time of failure. A clonal analysis of the V3 loop amino acid envelope sequences was performed from 6 of the 7Â subjects. Changes in V3 loop amino acid sequence differed between each of these different subjects, even for those infected with the same virus clade suggesting that that there are multiple diverse pathways to maraviroc resistance. The subjects who failed with CCR5-tropic virus and without a detectable maraviroc shift in susceptibility were not evaluated for genotypic resistance.</p>
<p>Of the 32 maraviroc virologic failures failing with CCR5-tropic virus, 20(63%) also had genotypic and/or phenotypic resistance to background drugs in the regimen (lamivudine, zidovudine).</p>
<p><span class="Italics">Tropism:</span> In both treatment-experienced and treatment-naive subjects, detection of CXCR4-using virus prior to initiation of therapy has been associated with a reduced virologic response to maraviroc. </p>
<p><span class="Italics">Antiretroviral Treatment-Experienced Subjects:</span> In the majority of cases, treatment failure on maraviroc was associated with detection of CXCR4-using virus (i.e., CXCR4- or dual/mixed-tropic) which was not detected by the tropism assay prior to treatment. CXCR4-using virus was detected at failure in approximately 55% of subjects who failed treatment on maraviroc by WeekÂ 48, as compared with 9% of subjects who experienced treatment failure in the placebo arm. To investigate the likely origin of the on-treatment CXCR4-using virus, a detailed clonal analysis was conducted on virus from 20Â representative subjects (16Â subjects from the maraviroc arms and 4Â subjects from the placebo arm) in whom CXCR4-using virus was detected at treatment failure. From analysis of amino acid sequence differences and phylogenetic data, it was determined that CXCR4-using virus in these subjects emerged from a low level of pre-existing CXCR4-using virus not detected by the tropism assay (which is population-based) prior to treatment rather than from a coreceptor switch from CCR5-tropic virus to CXCR4-using virus resulting from mutation in the virus.</p>
<p>Detection of CXCR4-using virus prior to initiation of therapy has been associated with a reduced virological response to maraviroc. Furthermore, subjects failing maraviroc twice daily at Week 48 with CXCR4-using virus hadÂ a lower median increase in CD4+ cell counts from baseline (+41Â cells/mm<span class="Sup">3</span>) than those subjects failing with CCR5-tropic virus (+162Â cells/mm<span class="Sup">3</span>). The median increase in CD4+ cell count in subjects failing in the placebo arm was +7Â cells/mm<span class="Sup">3</span>.</p>
<p><span class="Italics">Antiretroviral Treatment-Naive Subjects:</span> In a 96-week trial of antiretroviral treatment-naive subjects, 14% (12/85) who had CCR5-tropic virus at screening with an enhanced sensitivity tropism assay (TROFILE) and failed therapy on maraviroc had CXCR4-using virus at the time of treatment failure. A detailed clonal analysis was conducted in 2Â previously antiretroviral treatment-naive subjects enrolled in a Phase 2a monotherapy trial who had CXCR4-using virus detected after 10 days treatment with maraviroc. Consistent with the detailed clonal analysis conducted in treatment-experienced subjects, the CXCR4-using variants appear to emerge from outgrowth of a pre-existing undetected CXCR4-using virus. Screening with an enhanced sensitivity tropism assay reduced the number of maraviroc virologic failures with CXCR4- or dual/mixed-tropic virus at failure to 12 compared with 24 when screening with the original tropism assay. All but one (11/12; 92%) of the maraviroc failures failing with CXCR4 or dual/mixed-tropic virus also had genotypic and phenotypic resistance to the background drug lamivudine at failure and 33% (4 /12) developed zidovudine-associated resistance substitutions. </p>
<p>Subjects who had CCR5-tropic virus at baseline and failed maraviroc therapy with CXCR4-using virus had a median increase in CD4+ cell counts from baseline of +113Â cells/mm<span class="Sup">3</span> while those subjects failing with CCR5-tropic virus had an increase of +135Â cells/mm<span class="Sup">3</span>. The median increase in CD4+ cell count in subjects failing in the efavirenz arm was + 95Â cells/mm<span class="Sup">3</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<p><span class="Underline">Carcinogenesis:</span> Long-term oral carcinogenicity studies of maraviroc were carried out in rasH2 transgenic mice (6Â months) and in rats for up to 96Â weeks (females) and 104Â weeks (males). No drug-related increases in tumor incidence were found in mice at 1,500Â mg/kg/day and in male and female rats at 900Â mg/kg/day. The highest exposures in rats were approximately 11 times those observed in humans at the therapeutic dose of 300Â mg twice daily for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Underline">Mutagenesis:</span> Maraviroc was not genotoxic in the reverse mutation bacterial test (Ames test in <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">E. coli</span>), a chromosome aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and rat bone marrow micronucleus test.</p>
<p><span class="Underline">Impairment of Fertility:</span> Maraviroc did not impair mating or fertility of male or female rats and did not affect sperm of treated male rats at approximately 20-fold higher exposures (AUC) than in humans given the recommended 300-mg twice daily dose.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<a href="http://"></a><p class="First"></p>
<p>The clinical efficacy and safety of SELZENTRY are derived from analyses of data from 3 trials in adult subjects infected with CCR5-tropic HIV-1: A4001027 and A4001028 in antiretroviral treatment-experienced adult subjects and A4001026 in treatment-naive subjects. These trials were supported by a 48-week trial in antiretroviral treatment-experienced adult subjects infected with dual/mixed-tropic HIV-1, A4001029.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Trials A4001027 and A4001028 were double-blind, randomized, placebo-controlled, multicenter trials in subjects infected with CCR5-tropic HIV-1. Subjects were required to have an HIV-1 RNA of greater than 5,000Â copies/mL despite at least 6Â months of prior therapy with at least 1Â agent from 3 of the 4Â antiretroviral drug classes (â‰¥1Â NRTI, â‰¥1Â NNRTI, â‰¥2Â PIs, and/or enfuvirtide) or documented resistance to at least 1Â member of each class. All subjects received an optimized background regimen consisting of 3 to 6 antiretroviral agents (excluding low-dose ritonavir) selected on the basis of the subjectâ€™s prior treatment history and baseline genotypic and phenotypic viral resistance measurements. In addition to the optimized background regimen, subjects were then randomized in a 2:2:1 ratio to SELZENTRY 300Â mg once daily, SELZENTRY 300Â mg twice daily, or placebo. Doses were adjusted based on background therapy as described in <span class="Italics">Dosing and Administration</span>, Table 1.</p>
<p>In the pooled analysis for A4001027 and A4001028, the demographics and baseline characteristics of the treatment groups were comparable (Table 12). Of the 1,043 subjects with a CCR5 tropism result at screening, 7.6% had a dual/mixed-tropism result at the baseline visit 4 to 6Â weeks later. This illustrates the background change from CCR5- to dual/mixed-tropism result over time in this treatment-experienced population, prior to a change in antiretroviral regimen or administration of a CCR5 co-receptor antagonist.</p>
<a name="_Refid_53b0fcca-bd19-441d-9d1e-2044cd5ec"></a><table>
<caption><span>Table 12. Demographic and Baseline Characteristics of Subjects in Trials A4001027 and A4001028 </span></caption>
<col span="1" width="55%">
<col span="1" width="17%">
<col span="1" width="17%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First">SELZENTRY</p>
<p>Twice Daily</p>
<p>(NÂ =Â 426)</p>
</td>
<td>
<p class="First">Placebo</p>
<p>(NÂ =Â 209)</p>
</td>
</tr>
<tr>
<td><p class="First">Age (years)</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Mean (range)</p></td>
<td><p class="First">46.3 (21-73)</p></td>
<td><p class="First">45.7 (29-72)</p></td>
</tr>
<tr>
<td><p class="First">Sex</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Male</p></td>
<td><p class="First">382 (89.7%)</p></td>
<td><p class="First">185 (88.5%)</p></td>
</tr>
<tr>
<td><p class="First">Female</p></td>
<td><p class="First">44 (10.3%)</p></td>
<td><p class="First">24 (11.5%)</p></td>
</tr>
<tr>
<td><p class="First">Race</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">White</p></td>
<td><p class="First">363 (85.2%)</p></td>
<td><p class="First">178 (85.2%)</p></td>
</tr>
<tr>
<td><p class="First">Black</p></td>
<td><p class="First">51 (12.0%)</p></td>
<td><p class="First">26 (12.4%)</p></td>
</tr>
<tr>
<td><p class="First">Other</p></td>
<td><p class="First">12 (2.8%)</p></td>
<td><p class="First">5 (2.4%)</p></td>
</tr>
<tr>
<td><p class="First">Region</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">U.S.</p></td>
<td><p class="First">276 (64.8%)</p></td>
<td><p class="First">135 (64.6%)</p></td>
</tr>
<tr>
<td><p class="First">Non-U.S.</p></td>
<td><p class="First">150 (35.2%)</p></td>
<td><p class="First">74 (35.4%)</p></td>
</tr>
<tr>
<td><p class="First">Subjects with previous enfuvirtide use</p></td>
<td><p class="First">142 (33.3%)</p></td>
<td><p class="First">62 (29.7%)</p></td>
</tr>
<tr>
<td><p class="First">Subjects with enfuvirtide as part of OBT</p></td>
<td><p class="First">182 (42.7%)</p></td>
<td><p class="First">91 (43.5%)</p></td>
</tr>
<tr>
<td>
<p class="First">Baseline plasma HIV-1 RNA (log<span class="Sub">10</span> copies/mL)</p>
<p>Mean (range)</p>
</td>
<td><p class="First">4.85 (2.96-6.88)</p></td>
<td><p class="First">4.86 (3.46-7.07)</p></td>
</tr>
<tr>
<td>
<p class="First">Subjects with screening</p>
<p>viral load <span class="Underline">&gt;</span>100,000 copies/mL</p>
</td>
<td><p class="First">179 (42.0%)</p></td>
<td><p class="First">84 (40.2%)</p></td>
</tr>
<tr>
<td>
<p class="First">Baseline CD4+ cell count (cells/mm<span class="Sup">3</span>) </p>
<p>Median (range)</p>
</td>
<td><p class="First">167 (2-820)</p></td>
<td><p class="First">171 (1-675)</p></td>
</tr>
<tr>
<td><p class="First">Subjects with baseline CD4+ cell count â‰¤200Â cells/mm<span class="Sup">3</span>)</p></td>
<td><p class="First">250 (58.7%)</p></td>
<td><p class="First">118 (56.5%)</p></td>
</tr>
<tr>
<td><p class="First">Subjects with Overall Susceptibility Score (OSS):<span class="Sup">a</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">0</p></td>
<td><p class="First">57 (13.4%)</p></td>
<td><p class="First">35 (16.7%)</p></td>
</tr>
<tr>
<td><p class="First">1</p></td>
<td><p class="First">136 (31.9%)</p></td>
<td><p class="First">44 (21.1%)</p></td>
</tr>
<tr>
<td><p class="First">2</p></td>
<td><p class="First">104 (24.4%)</p></td>
<td><p class="First">59 (28.2%)</p></td>
</tr>
<tr>
<td><p class="First">â‰¥3</p></td>
<td><p class="First">125 (29.3%)</p></td>
<td><p class="First">66 (31.6%)</p></td>
</tr>
<tr>
<td><p class="First">Subjects with enfuvirtide resistance mutations</p></td>
<td><p class="First">90 (21.2%)</p></td>
<td><p class="First">45 (21.5%)</p></td>
</tr>
<tr>
<td><p class="First">Median number of resistance-associated:<span class="Sup">b</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">PI mutations</p></td>
<td><p class="First">10</p></td>
<td><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First">NNRTI mutations</p></td>
<td><p class="First">1</p></td>
<td><p class="First">1</p></td>
</tr>
<tr class="Last">
<td><p class="First">NRTI mutations</p></td>
<td><p class="First">6</p></td>
<td><p class="First">6</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>OSS - Sum of active drugs in OBT based on combined information from genotypic and phenotypic testing. </p>
<p><span class="Sup">b</span>Resistance mutations based on IAS guidelines.<span class="Sup">1</span></p>
<p>The Week 48 results for the pooled Trials A4001027 and A4001028 are shown in TableÂ 13.</p>
<a name="_Refid_793ceb08-5cc3-4601-924a-4f2b4d856"></a><table>
<caption><span>Table 13. Outcomes of Randomized Treatment at Week 48 Trials A4001027 and A4001028</span></caption>
<col span="1" width="70%">
<col span="1" width="15%">
<col span="1" width="12%">
<col span="1" width="18%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Outcome</p></td>
<td>
<p class="First">SELZENTRY</p>
<p>Twice Daily</p>
<p>(NÂ =Â 426)</p>
</td>
<td>
<p class="First">Placebo</p>
<p>(NÂ =Â 209)</p>
</td>
<td><p class="First">Mean Difference</p></td>
</tr>
<tr>
<td><p class="First">Mean change from Baseline to Week 48 in HIV-1 RNA (log<span class="Sub">10</span> copies/mL)</p></td>
<td><p class="First">-1.84</p></td>
<td><p class="First">-0.78</p></td>
<td><p class="First">-1.05 </p></td>
</tr>
<tr>
<td><p class="First">&lt;400Â copies/mL at Week 48</p></td>
<td><p class="First">239 (56%)</p></td>
<td><p class="First">47 (22%)</p></td>
<td><p class="First">34% </p></td>
</tr>
<tr>
<td><p class="First">&lt;50Â copies/mL at Week 48</p></td>
<td><p class="First">194 (46%)</p></td>
<td><p class="First">35 (17%)</p></td>
<td><p class="First">29% </p></td>
</tr>
<tr>
<td><p class="First">Discontinuations</p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Insufficient clinical response</p></td>
<td><p class="First">97 (23%)</p></td>
<td><p class="First">113 (54%)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Adverse events</p></td>
<td><p class="First">19 (4%)</p></td>
<td><p class="First">11 (5%)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Other</p></td>
<td><p class="First">27 (6%)</p></td>
<td><p class="First">18 (9%)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Subjects with treatment-emergent CDC Category C events </p></td>
<td><p class="First">22 (5%)</p></td>
<td><p class="First">16 (8%)</p></td>
<td></td>
</tr>
<tr class="Last">
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (during trial or within 28 days of last dose)</p></td>
<td><p class="First">9 (2%)<span class="Sup">a</span></p></td>
<td><p class="First">1 (0.5%)</p></td>
<td></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>One additional subject died while receiving open-label therapy with SELZENTRY subsequent to discontinuing double-blind placebo due to insufficient response.</p>
<p>After 48 weeks of therapy, the proportions of subjects with HIV-1 RNA &lt;400Â copies/mL receiving SELZENTRY compared with placebo were 56% and 22%, respectively. The mean changes in plasma HIV-1 RNA from baseline to Week 48 were â€“1.84 log<span class="Sub">10Â </span>copies/mL for subjects receiving SELZENTRY + OBT compared with â€“0.78 log<span class="Sub">10Â </span>copies/mL for subjects receiving OBT only. The mean increase in CD4+ cell count was higher on SELZENTRY twice daily + OBT (124Â cells/mm<span class="Sup">3</span>) than on placebo + OBT (60Â cells/mm<span class="Sup">3</span>).</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Trial A4001029 was an exploratory, randomized, double-blind, multicenter trial to determine the safety and efficacy of SELZENTRY in subjects infected with dual/mixed co-receptor tropic HIV-1. The inclusion/exclusion criteria were similar to those for Trials A4001027 and A4001028 above and the subjects were randomized in a 1:1:1 ratio to SELZENTRY once daily, SELZENTRY twice daily, or placebo. No increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> progression was observed in the subjects who received SELZENTRY. Use of SELZENTRY was not associated with a significant decrease in HIV-1 RNA compared with placebo in these subjects and no adverse effect on CD4+ cell count was noted.</p>
<p>
Â 
</p>
<a href="http://"></a><p></p>
<p>Trial A4001026 is an ongoing, randomized, double-blind, multicenter trial in subjects infected with CCR5-tropic HIV-1 classified by the original TROFILE tropism assay. Subjects were required to have plasma HIV-1 RNA â‰¥2,000Â copies/mL and could not have: 1) previously received any antiretroviral therapy for &gt;14Â days, 2) an active or recent <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> or a suspected primary HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or 3) phenotypic or genotypic resistance to zidovudine, lamivudine, or efavirenz. Subjects were randomized in a 1:1:1 ratio to SELZENTRY 300Â mg once daily, SELZENTRY 300Â mg twice daily, or efavirenz 600Â mg once daily, each in combination with zidovudine/lamivudine. The efficacy and safety of SELZENTRY are based on the comparison of SELZENTRY twice daily versus efavirenz. In a pre-planned interim analysis at 16Â weeks, SELZENTRY 300 mg once daily failed to meet the pre-specified criteria for demonstrating non-inferiority and was discontinued.</p>
<p>The demographic and baseline characteristics of the maraviroc and efavirenz treatment groups were comparable (Table 14). Subjects were stratified by screening HIV-1 RNA levels and by geographic region. The median CD4+Â cell counts and mean HIV-1 RNA at baseline were similar for both treatment groups.</p>
<a name="_Refid_72df88dd-fbc3-4b27-a61f-03b68e3f9"></a><table>
<caption><span>Table 14. Demographic and Baseline Characteristics of Subjects in Trial A4001026</span></caption>
<col span="1" width="30%">
<col span="1" width="44%">
<col span="1" width="41%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td>
<p class="First">SELZENTRY 300Â mg Twice Daily + Zidovudine/Lamivudine</p>
<p>(NÂ =Â 360)</p>
</td>
<td>
<p class="First">Efavirenz 600Â mg Once Daily + Zidovudine/Lamivudine</p>
<p>(NÂ =Â 361)</p>
</td>
</tr>
<tr>
<td><p class="First">Age (years)</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Mean</p></td>
<td><p class="First">36.7</p></td>
<td><p class="First">37.4</p></td>
</tr>
<tr>
<td><p class="First">Range</p></td>
<td><p class="First">20-69</p></td>
<td><p class="First">18-77</p></td>
</tr>
<tr>
<td><p class="First">Female, n%</p></td>
<td><p class="First">104 (29)</p></td>
<td><p class="First">102 (28)</p></td>
</tr>
<tr>
<td><p class="First">Race, n%</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">White</p></td>
<td><p class="First">204 (57)</p></td>
<td><p class="First">198 (55)</p></td>
</tr>
<tr>
<td><p class="First">Black</p></td>
<td><p class="First">123 (34)</p></td>
<td><p class="First">133 (37)</p></td>
</tr>
<tr>
<td><p class="First">Asian</p></td>
<td><p class="First">6 (2)</p></td>
<td><p class="First">5 (1)</p></td>
</tr>
<tr>
<td><p class="First">Other</p></td>
<td><p class="First">27 (8)</p></td>
<td><p class="First">25 (7)</p></td>
</tr>
<tr>
<td><p class="First">Median (range) CD4+ cell count (cells/ÂµL)</p></td>
<td><p class="First">241 (5-1,422)</p></td>
<td><p class="First">254 (8-1,053)</p></td>
</tr>
<tr class="Last">
<td><p class="First">Median (range) HIV-1 RNA (log<span class="Sub">10 </span>copies/mL)</p></td>
<td><p class="First">4.9 ( 3-7)</p></td>
<td><p class="First">4.9 (3-7)</p></td>
</tr>
</tbody>
</table>
<p>The treatment outcomes at 96Â weeks for Trial A4001026 are shown in Table 15. Treatment outcomes are based on reanalysis of the screening samples using a more sensitive tropism assay, Enhanced sensitivity TROFILE HIV tropism assay, which became available after the Week 48 analysis, approximately 15% of the subjects identified as CCR5-tropic in the original analysis had dual/mixed- or CXCR4-tropic virus. Screening with enhanced sensitivity version of the TROFILE tropism assay reduced the number of maraviroc virologic failures with CXCR4- or dual/mixed-tropic virus at failure to 12 compared with 24 when screening with the original TROFILE HIV tropism assay.</p>
<a name="_Refid_77472d81-449d-45a2-a341-60cb3163a"></a><table>
<caption><span>Table 15: Trial Outcome (Snapshot) at Week 96 Using Enhanced Sensitivity Assay<span class="Sup">a</span></span></caption>
<col span="1" width="36%">
<col span="1" width="50%">
<col span="1" width="30%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Outcome at Week 96<span class="Sup">b</span></p></td>
<td>
<p class="First">SELZENTRY 300Â mg Twice Daily + Zidovudine/Lamivudine</p>
<p>NÂ =Â 311</p>
<p>n (%)</p>
</td>
<td>
<p class="First">Efavirenz 600 mg Once Daily +</p>
<p>Zidovudine/Lamivudine</p>
<p>NÂ =Â 303</p>
<p>n (%)</p>
</td>
</tr>
<tr>
<td>
<p class="First">Virologic Responders: </p>
<p>(HIV-1 RNA &lt;400Â copies/mL)</p>
</td>
<td><p class="First">199 (64)</p></td>
<td><p class="First">195 (64)</p></td>
</tr>
<tr>
<td><p class="First">Virologic Failure:</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><ul><li>Non-sustained HIV-1 RNA suppression</li></ul></td>
<td><p class="First">39 (13)</p></td>
<td><p class="First">22 (7)</p></td>
</tr>
<tr>
<td><ul><li>HIV-1 RNA never suppressed </li></ul></td>
<td><p class="First">9 (3)</p></td>
<td><p class="First">1 (&lt;1)</p></td>
</tr>
<tr>
<td>
<p class="First">Virologic Responders:</p>
<p>(HIV-1 RNA &lt;50Â copies/mL)</p>
</td>
<td><p class="First">183 (59)</p></td>
<td><p class="First">190 (63)</p></td>
</tr>
<tr>
<td><p class="First">Virologic Failure:</p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><ul><li>Non-sustained HIV-1 RNA suppression</li></ul></td>
<td><p class="First">43 (14)</p></td>
<td><p class="First">25 (8)</p></td>
</tr>
<tr>
<td><ul><li>HIV-1 RNA never suppressed</li></ul></td>
<td><p class="First">21 (7)</p></td>
<td><p class="First">3 (1)</p></td>
</tr>
<tr><td><p class="First">Discontinuations due to:</p></td></tr>
<tr>
<td><ul><li>Adverse events</li></ul></td>
<td><p class="First">19 (6)</p></td>
<td><p class="First">47 (16)</p></td>
</tr>
<tr>
<td><ul><li><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></li></ul></td>
<td><p class="First">2 (1)</p></td>
<td><p class="First">2 (1)</p></td>
</tr>
<tr class="Last">
<td><ul><li>Other<span class="Sup">c</span>
</li></ul></td>
<td><p class="First">43 (14)</p></td>
<td><p class="First">36 (12)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>The total number of subjects (Ns) in Table 15 represents the subjects who had a CCR5-tropic virus in the reanalysis of screening samples using the more sensitive tropism assay. This reanalysis reclassified approximately 15% of subjects shown in Table 14 as having dual/mixed- or CXCR4-tropic virus. These numbers are different than those presented in Table 14 because the numbers in Table 14 reflect the subjects with CCR5-tropic virus according to the original tropism assay. </p>
<p><span class="Sup">b</span>Week 48 results: Virologic responders (&lt;400): 228/311 (73%) in SELZENTRY, 219/303 (72%) in efavirenz;</p>
<p>Virologic responders (&lt;50): 213/311 (69 %) in SELZENTRY, 207/303 (68%) in efavirenz</p>
<p><span class="Sup">c</span>Other reasons for discontinuation include lost to follow-up, withdrawn, protocol violation, and other.</p>
<p>The median increase from baseline in CD4+ cell counts at Week 96 was 184 cells/mm<span class="Sup">3</span> for the arm receiving SELZENTRY compared with 155Â cells/mm<span class="Sup">3</span> for the efavirenz arm. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<a href="http://"></a><p class="First"></p>
<ol><li>IAS-USA <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span> Mutations Figures. http://www.iasusa.org/pub/topics/2006/issue3/125.pdf </li></ol>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<a href="http://"></a><p class="First"></p>
<p>SELZENTRY film-coated tablets are available as follows:</p>
<p>150- and 300-mg tablets are blue, biconvex, oval, film-coated tablets debossed with â€œMVC 150â€? or â€œMVC 300â€? on one side and plain on the other.</p>
<p>Bottle packs 150-mg tablets: 60 tablets (NDC 49702-223-18).</p>
<p>Bottle packs 300-mg tablets: 60 tablets (NDC 49702-224-18).</p>
<p>SELZENTRY film-coated tablets should be stored at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions permitted between 15<span class="Sup">o</span>C and 30<span class="Sup">o</span>C (59<span class="Sup">o</span>F-86<span class="Sup">o</span>F) [see USP Controlled Room Temperature].</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<a href="http://"></a><p class="First"></p>
<p><span class="Italics">See FDA-approved patient labeling (Medication Guide)</span></p>
<p>Patients should be informed that liver problems including life-threatening cases have been reported with SELZENTRY. Patients should be informed that if they develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> following use of SELZENTRY (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, skin or eyes look yellow, dark urine, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), they should stop SELZENTRY and seek medical evaluation immediately. Patients should understand that laboratory tests for liver enzymes and bilirubin will be ordered prior to starting SELZENTRY, at other times during treatment, and if they develop severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> on treatment <span class="Italics">[see Warnings and Precautions (5.1), (5.2)]</span>.</p>
<p>Patients should be informed that SELZENTRY is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>.</p>
<p>Patients should remain under the care of a physician when using SELZENTRY. </p>
<p>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
<li>
<span class="Bold">Do not breastfeed.</span> We do not know if SELZENTRY can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
<p>Patients should be advised that it is important to take all their antiâ€‘HIV medicines as prescribed and at the same time(s) each day. SELZENTRY must always be used in combination with other antiretroviral drugs. Patients should not alter the dose or discontinue therapy without consulting their physician. If a dose is missed, patients should take the next dose of SELZENTRY as soon as possible and then take their next scheduled dose at its regular time. If it is less than 6Â hours before their next scheduled dose, they should not take the missed dose and should instead wait and take the next dose at the regular time. </p>
<p>Patients should be advised that when their supply of SELZENTRY starts to run low, they should ask their doctor or pharmacist for a refill. </p>
<p>Caution should be used when administering SELZENTRY<span class="Sup"></span>in patients with a history of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> or on concomitant medication known to lower blood pressure. Patients should be advised that if they experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> while taking SELZENTRY, they should avoid driving or operating machinery.</p>
<p>TROFILE<span class="Sup">Â®</span> is a registered trademark of Monogram Biosciences, Inc.</p>
<p>Manufactured for:<br></p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>Pfizer Manufacturing Deutschland GmbH</p>
<p>Freiburg, Germany</p>
<p>Â©2013, ViiV Healthcare. All rights reserved.</p>
<p>SEL: 7PI</p>
<p>PHARMACISTâ€‘DETACH HERE AND GIVE MEDICATION GUIDE TO PATIENT</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-17"></a><p></p>
<h1>SPL MEDGUIDE</h1>
<a href="http://"></a><p class="First"></p>
<p><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">SELZENTRY</span><span class="Sup">Â®</span> (sell-ZEN-tree) <span class="Bold">Tablets</span></p>
<p><span class="Bold">(</span><span class="Bold">maraviroc</span><span class="Bold">)</span></p>
<p>Read the Medication Guide that comes with SELZENTRY before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about SELZENTRY?</span></p>
<p><span class="Bold">Serious side effects have occurred with SELZENTRY, including liver problems (liver toxicity). </span>An <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may happen before liver problems occur. Stop taking SELZENTRY and call your healthcare provider right away if you get any of the following symptoms:</p>
<ul>
<li>an <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> on your body (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>)</li>
<li>yellowing of your skin or whites of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark (tea-colored) urine</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>upper right stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">What is SELZENTRY? </span></p>
<p>SELZENTRY is an anti-HIV medicine called a CCR5 antagonist. HIV-1 (Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus) is the virus that causes AIDS (<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span>).</p>
<p>SELZENTRY is used with other anti-HIV medicines in adults with CCR5-tropic HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Use of SELZENTRY is not recommended in people with dual/mixed or CXCR4-tropic HIV-1.</p>
<ul>
<li>SELZENTRY will not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>People taking SELZENTRY may still develop <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> or other conditions that happen with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>It is very important that you stay under the care of your healthcare provider during treatment with SELZENTRY.</li>
<li>The long-term effects of SELZENTRY are not known at this time.</li>
</ul>
<p>SELZENTRY has not been studied in children less than 16Â years of age.</p>
<p><span class="Bold">General information about SELZENTRY</span></p>
<p>SELZENTRY does not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and you may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. You should remain under the care of a doctor when using SELZENTRY.</p>
<p>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<ul>
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p><span class="Bold">How does SELZENTRY work?</span></p>
<p>HIV-1 enters cells in your blood by attaching itself to structures on the surface of the cell called receptors. SELZENTRY blocks a specific receptor called CCR5 that CCR5-tropic HIV-1 uses to enter CD4 or T-cells in your blood. Your healthcare provider will do a blood test to see if you have been infected with CCR5-tropic HIV-1 before prescribing SELZENTRY for you.</p>
<ul>
<li>When used with other anti-HIV medicines, SELZENTRY may:</li>
<li>reduce the amount of HIV-1 in your blood. This is called â€œviral loadâ€?.</li>
<li>increase the number of white blood cells called T (CD4) cells.</li>
</ul>
<p>SELZENTRY does not work in all people with CCR5-tropic HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Bold">Who should not take SELZENTRY? </span></p>
<p>People with severe kidney problems or who are on hemodialysis and are taking certain other medications should not take SELZENTRY. Talk to your healthcare provider before taking this medicine if you have kidney problems.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking SELZENTRY?</span></p>
<p><span class="Bold">Before you take SELZENTRY, </span><span class="Bold">tell your healthcare provider</span><span class="Bold"> if you:</span></p>
<ul>
<li>have liver problems including a history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C.</li>
<li>have heart problems.</li>
<li>have kidney problems.</li>
<li>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> or take medicines to lower blood pressure.</li>
<li>have any other medical condition.</li>
<li>are pregnant or plan to become pregnant. It is not known if SELZENTRY may harm your unborn baby. <p class="First"><span class="Bold">Antiretroviral Pregnancy Registry. </span>There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.</p>
</li>
</ul>
<ul><li>are breastfeeding or plan to breastfeed. <span class="Bold">Do not breastfeed.</span> We do not know if SELZENTRY can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk. Talk with your healthcare provider about the best way to feed your baby.</li></ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements. Certain other medicines may affect the levels of SELZENTRY in your blood. Your healthcare provider may need to change your dose of SELZENTRY when you take it with certain medicines.</p>
<p>The levels of SELZENTRY in your blood may change and your healthcare provider may need to adjust your dose of SELZENTRY when taking any of the following medications together with SELZENTRY:</p>
<table>
<col span="1" width="62%">
<col span="1" width="37%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">- darunavir (Prezista<span class="Sup">Â®</span>)</p></td>
<td><p class="First">- delavirdine (Rescriptor<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- lopinavir/ritonavir (Kaletra<span class="Sup">Â®</span>, Norvir<span class="Sup">Â®</span>) </p></td>
<td><p class="First">- ketoconazole (Nizoral<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- atazanavir (Reyataz<span class="Sup">Â®</span>) </p></td>
<td><p class="First">- itraconazole (Sporanox<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- saquinavir (Invirase<span class="Sup">Â®</span>) </p></td>
<td><p class="First">- clarithromycin (Biaxin<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- nelfinavir (Viracept<span class="Sup">Â®</span>) </p></td>
<td><p class="First">- nefazodone (Serzone<span class="Sup">Â®)</span></p></td>
</tr>
<tr>
<td><p class="First">- indinavir (Crixivan<span class="Sup">Â®</span>) </p></td>
<td><p class="First">- telithromycin (Ketek<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- fosamprenavir (Lexiva<span class="Sup">Â®</span>) </p></td>
<td><p class="First">- efavirenz (Sustiva<span class="Sup">Â®</span>, Atripla<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- etravirine (Intelence<span class="Sup">Â®</span>)- rifampin (Rifadin<span class="Sup">Â®</span>, Rifater<span class="Sup">Â®</span>)</p></td>
<td><p class="First">- rifampin (Rifadin<span class="Sup">Â®</span>, Rifater<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- carbamezepine (Tegretol<span class="Sup">Â®</span>) </p></td>
<td><p class="First">-phenobarbital (Luminal<span class="Sup">Â®</span>)</p></td>
</tr>
<tr>
<td><p class="First">- phenytoin (Dilantin<span class="Sup">Â®</span>)</p></td>
<td></td>
</tr>
<tr class="Last">
<td><p class="First">- ritonavir (Norvir<span class="Sup">Â®</span></p></td>
<td></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Do not take products that contain St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>). St. Johnâ€™s wort may lower the levels of SELZENTRY in your blood so that it will not work to treat your CCR5-tropic HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p><span class="Bold">Know the medicines you take.</span> Keep a list of your medicines. Show the list to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take SELZENTRY?</span></p>
<p><span class="Bold">Take SELZENTRY exactly as prescribed by your healthcare provider.</span> SELZENTRY comes in 150-mg and 300-mg tablets. Your healthcare provider will prescribe the dose that is right for you.</p>
<ul>
<li>Take SELZENTRY 2 times a day.</li>
<li>Swallow SELZENTRY tablets whole. Do not chew the tablets.</li>
<li>Take SELZENTRY tablets with or without food.</li>
<li>Always take SELZENTRY with other anti-HIV drugs as prescribed by your healthcare provider.</li>
</ul>
<p><span class="Bold">Do not change your dose or stop taking SELZENTRY or your other anti-HIV medicines without first talking with your healthcare provider.</span></p>
<ul>
<li>If you take too much SELZENTRY, call your healthcare provider or the poison control center right away.</li>
<li>If you forget to take SELZENTRY, take the next dose of SELZENTRY as soon as possible and then take your next scheduled dose at its regular time. If it is less than 6Â hours before your next dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not take a double dose to make up for a missed dose.</li>
<li>It is very important to take all your anti-HIV medicines as prescribed. This can help your medicines work better. It also lowers the chance that your medicines will stop working to fight HIV-1 (<span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>).</li>
<li>When your SELZENTRY supply starts to run low, ask your healthcare provider or pharmacist for a refill. This is very important because the amount of virus in your blood may increase and SELZENTRY could stop working if it is stopped for even a short period of time.</li>
</ul>
<p><span class="Bold">What are the possible side effects of SELZENTRY?</span></p>
<p><span class="Bold">There have been serious side effects when SELZENTRY has been given with other anti-HIV drugs including:</span></p>
<ul><li>
<span class="Bold">Liver problems.</span> See â€œWhat is the most important information I should know about SELZENTRY?â€?</li></ul>
<ul><li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> Severe and potentially life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported in some patients taking SELZENTRY. If you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with any of the following symptoms, stop using SELZENTRY and contact your doctor right away:<ul>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>generally ill feeling</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or sores in your mouth</li>
<li><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of the skin</li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the eyes</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the mouth or face or lips</li>
<li>problems breathing</li>
<li>yellowing of the skin or whites of your eyes</li>
<li>dark or tea colored urine</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, aching, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> on the right side below the ribs</li>
<li>loss of appetite</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
</ul>
</li></ul>
<ul>
<li>
<span class="Bold">Heart problems</span> including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> when standing up (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>).</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> when standing up can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. Do not drive a car or operate heavy machinery if you have <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> while taking SELZENTRY.</li>
<li>
<span class="Bold">Changes in your immune system.</span> A condition called <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> can happen when you start taking HIV medicines. Your immune system may get stronger and could begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, herpes virus, or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>. Tell your healthcare provider if you develop new symptoms after starting your HIV medicines.</li>
<li>
<span class="Bold">Possible chance of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or cancer.</span> SELZENTRY affects other immune system cells and therefore may possibly increase your chance for getting other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or cancer.</li>
</ul>
<p><span class="Bold">The most common side effects of SELZENTRY include </span><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">colds</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Tell your healthcare provider about any side effect that bothers you or does not go away.</p>
<p>These are not all of the side effects with SELZENTRY. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store SELZENTRY?</span></p>
<ul>
<li>Store SELZENTRY tablets at room temperature from 59Â°F to 86Â°F (15Â°C to 30Â°C).</li>
<li>Safely throw away medicine that is out of date or that you no longer need.</li>
</ul>
<p><span class="Bold">Keep SELZENTRY and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about SELZENTRY</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in Medication Guides. Do not use SELZENTRY for a condition for which it was not prescribed. Do not give SELZENTRY to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about SELZENTRY. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for more information about SELZENTRY that is written for health professionals.</p>
<p>For more information, go to www.selzentry.com.</p>
<p><span class="Bold">What are the ingredients in SELZENTRY?</span></p>
<p><span class="Bold">Active ingredient</span>: maraviroc</p>
<p><span class="Bold">Inactive ingredients: </span>microcrystalline cellulose, dibasic calcium phosphate (anhydrous), sodium starch glycolate, magnesium stearate</p>
<p><span class="Bold">Film-coat:</span> FD&amp;C blue #2 aluminum lake, soya lecithin, polyethylene glycol (macrogol 3350), polyvinyl alcohol, talc, and titanium dioxide</p>
<p>The brands listed are the trademarks or registered marks of their respective owners and are not trademarks of ViiV Healthcare. The makers of these brands are not affiliated with and do not endorse ViiV Healthcare or its products.</p>
<p>This Medication Guide has been approved by the US Food and Drug Administration.</p>
<p>Manufactured for:<br></p>
<p>ViiV Healthcare</p>
<p>Research Triangle Park, NC 27709</p>
<p>by:</p>
<p>Pfizer Manufacturing Deutschland GmbH</p>
<p>Freiburg, Germany</p>
<p>Â©2013, ViiV Healthcare. All rights reserved.</p>
<p>February 2013</p>
<p>SEL:4MG</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
    DRUG: SELZENTRY <br>GENERIC: maraviroc<br>DOSAGE: TABLET, FILM COATED<br>ADMINSTRATION: ORAL<br>NDC: 52125-011-02<br>STRENGTH:150 mg<br>COLOR: blue<br>SHAPE: OVAL<br>SCORE: No score<br>SIZE: 12 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=74fba35e-931e-44d8-97e0-d243bb687a71&amp;name=MM2.jpg"></div>
<div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=74fba35e-931e-44d8-97e0-d243bb687a71&amp;name=MM3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SELZENTRYÂ 		
					</strong><br><span class="contentTableReg">maraviroc tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-011(NDC:49702-223)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MARAVIROC</strong> (MARAVIROC) </td>
<td class="formItem">MARAVIROC</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED SOYBEAN LECITHIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET, FILM COATED) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MVC150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-011-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022128</td>
<td class="formItem">02/18/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e3b0c38a-4f06-47be-869f-45aa30b118f2</div>
<div>Set id: 74fba35e-931e-44d8-97e0-d243bb687a71</div>
<div>Version: 2</div>
<div>Effective Time: 20130218</div>
</div>
</div>Â <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
